[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 112
1. Cunningham I: Extramedullary sites of leukemia relapse after transplant. Leuk Lymphoma; 2006 Sep;47(9):1754-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramedullary sites of leukemia relapse after transplant.
  • Recurrent or residual leukemia found in extramedullary sites after intensive treatments adversely affects prognosis.
  • The most commonly reported sites are soft tissue in acute leukemias and bone in CML.
  • Extramedullary relapse occurred typically within 2 years in ALL, but later in one-third of myeloid leukemias.
  • Most testicular relapses reported in AML followed non-TBI conditioning.
  • Marrow relapse was not inevitable if aggressive treatment was begun early.
  • Intensive therapy has produced lengthy remissions in cases of acute leukemias involving various sites, whereas CML cases, particularly involving bone, were most resistant to treatment.
  • Heightened awareness and aggressive treatment should improve the prospect for cure after extramedullary relapse.
  • [MeSH-major] Bone Neoplasms / pathology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Leukemia, Myeloid, Acute / pathology. Neoplasm Recurrence, Local / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Soft Tissue Neoplasms / pathology. Stem Cell Transplantation


2. Sultana TA, Abdul Mottalib M, Islam S, Khan MA, Choudhury S: Rt-PCR method for diagnosis and follow-up of hematological malignancies: first approach in Bangladesh. Bangladesh Med Res Counc Bull; 2008 Apr;34(1):1-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rt-PCR method for diagnosis and follow-up of hematological malignancies: first approach in Bangladesh.
  • Nested reverse-transcriptase polymerase chain reaction (rt-PCR) was performed on 58 leukemia patients at BIRDEM Laboratory, as a pioneering work in Bangladesh.
  • Thirty of themwere examined for the presence of BCR-ABL being clinically and morphologically diagnosed as chronic myeloid leukemia (CML) and 28 for PML-RARalpha fusion transcripts being clinically and morphologically diagnosed as acute promyelocytic leukemia (APL/ AML M3).
  • In present times, the detection of minimal residual disease in patients undergoing treatment for hematological malignancies has become an important goal, not only to monitor the effectiveness of therapy but also to detect an impending relapse.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Leukemia, Promyelocytic, Acute / diagnosis. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18783070.001).
  • [ISSN] 0377-9238
  • [Journal-full-title] Bangladesh Medical Research Council bulletin
  • [ISO-abbreviation] Bangladesh Med Res Counc Bull
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Bangladesh
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 5688UTC01R / Tretinoin; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


3. Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, O'Reilly RJ, Horowitz MM, Dupont B: Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood; 2005 Jun 15;105(12):4878-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.
  • In 178 patients receiving T-cell-depleted HLA-identical sibling transplants for acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), or myelodysplastic syndrome (MDS), analysis of donor KIR genotype with HLA genotype demonstrated that 62.9% of the patients lacked an HLA ligand for donor-inhibitory KIR.
  • Lack of HLA ligand for donor-inhibitory KIR (missing KIR ligand) had no effect on disease-free survival (DFS), overall survival (OS), or relapse in patients receiving transplants for CML and ALL.
  • In patients with AML and MDS, however, there was a significant missing KIR ligand effect on DFS (P = .014; hazard ratio [HR], 0.53; 95% confidence interval [95% CI], 0.28-0.88) and OS (P = .03; HR, 0.53; 95% CI, 0.3-0.93).
  • Incidence of relapse was also lower in patients with AML and MDS who lacked the HLA ligand for donor-inhibitory KIR (P = .04; HR, 0.41; 95% CI, 0.18-0.97).
  • AML and MDS patients lacking 2 HLA ligands for donor-inhibitory KIR had the highest DFS (P = .002) and OS (P = .003).
  • These data indicate that the absence of class I ligand in the recipient for donor-inhibitory KIR can be a prognostic factor for transplantation outcome in HLA-identical sibling transplantation and that the lack of HLA-C or -B ligands for donor-inhibitory KIR can contribute to improved outcomes for patients with AML and MDS.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Immunol. 1999;17:189-220 [10358757.001]
  • [Cites] Tissue Antigens. 1995 Nov;46(5):355-67 [8838344.001]
  • [Cites] Blood. 1999 Jul 15;94(2):434-41 [10397710.001]
  • [Cites] Transplantation. 1999 Jul 15;68(1):87-8 [10428273.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2594-600 [15536148.001]
  • [Cites] Transplantation. 1999 Dec 15;68(11):1784-9 [10609957.001]
  • [Cites] Br J Haematol. 2000 Mar;108(4):778-83 [10792283.001]
  • [Cites] Bone Marrow Transplant. 2000 Aug;26(3):287-90 [10967567.001]
  • [Cites] Tissue Antigens. 2000 Oct;56(4):313-26 [11098931.001]
  • [Cites] Tissue Antigens. 2001 Jan;57(1):46-54 [11169258.001]
  • [Cites] Immunogenetics. 2001;52(3-4):195-205 [11220621.001]
  • [Cites] J Immunol. 2001 Mar 1;166(5):2992-3001 [11207248.001]
  • [Cites] Tissue Antigens. 2001 Mar;57(3):221-9 [11285130.001]
  • [Cites] Tissue Antigens. 2001 Apr;57(4):358-62 [11380947.001]
  • [Cites] J Immunol. 2002 Mar 1;168(5):2307-15 [11859120.001]
  • [Cites] Annu Rev Immunol. 2002;20:217-51 [11861603.001]
  • [Cites] J Immunol. 1997 Jun 1;158(11):5237-41 [9164941.001]
  • [Cites] Biol Blood Marrow Transplant. 1997 Jun;3(2):65-75 [9267666.001]
  • [Cites] Immunity. 1997 Dec;7(6):739-51 [9430220.001]
  • [Cites] Science. 2002 Mar 15;295(5562):2097-100 [11896281.001]
  • [Cites] Immunity. 1997 Dec;7(6):753-63 [9430221.001]
  • [Cites] Immunology. 1997 Dec;92(4):567-70 [9497500.001]
  • [Cites] J Clin Invest. 1998 May 1;101(9):1835-42 [9576746.001]
  • [Cites] Blood. 1999 Jan 15;93(2):467-80 [9885208.001]
  • [Cites] Immunogenetics. 2002 Mar;53(12):1009-19 [11904677.001]
  • [Cites] Cytotherapy. 2001;3(6):467-81 [11953031.001]
  • [Cites] Genes Immun. 2002 Apr;3(2):86-95 [11960306.001]
  • [Cites] J Immunol. 2002 Jul 1;169(1):239-47 [12077250.001]
  • [Cites] Immunology. 2002 Jul;106(3):373-80 [12100725.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1935-47 [12200350.001]
  • [Cites] J Immunol. 2002 Nov 1;169(9):5118-29 [12391228.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3825-7 [12393440.001]
  • [Cites] Immunogenetics. 2002 Nov;54(8):543-50 [12439616.001]
  • [Cites] Immunol Rev. 2002 Oct;188:9-21 [12445277.001]
  • [Cites] Nat Rev Immunol. 2003 Feb;3(2):108-22 [12563295.001]
  • [Cites] Int J Hematol. 2003 May;77(4):399-407 [12774932.001]
  • [Cites] Eur J Immunogenet. 2003 Jun;30(3):213-21 [12787000.001]
  • [Cites] Blood. 2003 Aug 1;102(3):814-9 [12689936.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1389-96 [12714493.001]
  • [Cites] Br J Haematol. 2003 Oct;123(2):323-6 [14531915.001]
  • [Cites] J Immunol. 2004 Jan 1;172(1):644-50 [14688377.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1521-6 [14504099.001]
  • [Cites] Tissue Antigens. 2004 Mar;63(3):204-11 [14989709.001]
  • [Cites] Exp Mol Pathol. 2004 Apr;76(2):90-8 [15010286.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2860-1; author reply 2862 [15033884.001]
  • [Cites] Nat Rev Immunol. 2004 Mar;4(3):190-8 [15039756.001]
  • [Cites] Science. 2004 Aug 6;305(5685):872-4 [15297676.001]
  • [Cites] Curr Opin Immunol. 2004 Oct;16(5):634-43 [15342011.001]
  • [Cites] J Immunol. 2004 Oct 1;173(7):4273-6 [15383555.001]
  • [Cites] J Exp Med. 2004 Oct 18;200(8):957-65 [15477349.001]
  • [Cites] Nature. 1986 Feb 20-26;319(6055):675-8 [3951539.001]
  • [Cites] Adv Immunol. 1989;47:187-376 [2683611.001]
  • [Cites] Blood. 1990 Jun 1;75(11):2250-62 [2189508.001]
  • [Cites] Eur J Immunol. 1994 Oct;24(10):2294-8 [7925558.001]
  • [Cites] J Exp Med. 1994 Oct 1;180(4):1235-42 [7931060.001]
  • [Cites] Transplantation. 1995 Jun 27;59(12):1734-6 [7604444.001]
  • [Cites] J Exp Med. 1996 Apr 1;183(4):1817-27 [8666938.001]
  • [Cites] Blood. 1999 Jul 1;94(1):333-9 [10381530.001]
  • (PMID = 15731175.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI49213; United States / NCI NIH HHS / CA / CA08748; United States / NCI NIH HHS / CA / CA23766; United States / NHLBI NIH HHS / HL / HL070053
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epitopes; 0 / HLA Antigens; 0 / HLA-B Antigens; 0 / HLA-C Antigens; 0 / Ligands; 0 / Oligonucleotide Probes; 0 / Receptors, Immunologic; 0 / Receptors, KIR
  • [Other-IDs] NLM/ PMC1894998
  •  go-up   go-down


Advertisement
4. Kondo T, Yasumoto A, Arita K, Sugita J, Shigematsu A, Okada K, Takahata M, Onozawa M, Kahata K, Takeda Y, Obara M, Yamamoto S, Endo T, Nishio M, Sato N, Tanaka J, Hashino S, Koike T, Asaka M, Imamura M: Successful treatment of acute myelogenous leukemia with favorable cytogenetics by reduced-intensity stem cell transplantation. Int J Hematol; 2010 Mar;91(2):310-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of acute myelogenous leukemia with favorable cytogenetics by reduced-intensity stem cell transplantation.
  • Acute myelogenous leukemia (AML) with favorable cytogenetics responds well to chemotherapy.
  • If the leukemia relapses, allogenic hematopoietic stem transplantation (allo-HSCT) is considered as a treatment option.
  • Since the efficacy of reduced-intensity stem cell transplantation (RIST) for AML with favorable cytogenetics has not been established, we retrospectively analyzed the outcomes of allo-HSCT in AML patients according to cytogenetic risks.
  • The outcome of allo-HSCT for AML patients with favorable cytogenetics seemed to be superior to that for AML patients with intermediate cytogenetics.
  • In AML patients with favorable cytogenetics, the 3-year overall survival (OS) and relapse-free survival (RFS) rates were 88 and 76%, respectively, in the RIST group.
  • The outcome of RIST for AML patients with favorable cytogenetics was comparable to that for patients who received CST despite the more advanced age and greater organ dysfunction in RIST group than in CST group.
  • Moreover, there was no relapse in patients with favorable cytogenetics who were in hematological remission prior to RIST.
  • Thus, RIST for AML patients with favorable cytogenetics in remission is safe and effective.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Transplantation Conditioning / methods


5. Armand P, Kim HT, DeAngelo DJ, Ho VT, Cutler CS, Stone RM, Ritz J, Alyea EP, Antin JH, Soiffer RJ: Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant; 2007 Jun;13(6):655-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.
  • Cytogenetics has an important impact on the prognosis of patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS).
  • In this study, we retrospectively analyzed data on 556 patients with AML or MDS transplanted at our institution.
  • We examined, in multivariate analyses, the contribution of cytogenetics to survival, relapse, and nonrelapse mortality for the 476 patients with de novo disease.
  • When classified by this new scheme, cytogenetics was the strongest prognostic factor for overall survival in our cohort, through its impact on the risk of relapse (and not on nonrelapse mortality).
  • After accounting for cytogenetics, patients with therapy-related AML or MDS had an equivalent outcome to those with de novo disease.
  • This study demonstrates the impact of cytogenetics on the risk of relapse and death for patients with both de novo and therapy-related disease undergoing transplantation; it also emphasizes the necessity of using cytogenetics to stratify patients entering clinical trials, and provides a system for doing so, which can be validated in a multi-institutional database.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 1999 Dec;84(12):1085-7 [10586209.001]
  • [Cites] Blood. 2006 May 15;107(10):4011-20 [16455956.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2134-41 [11304765.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2482-92 [11331327.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Leukemia. 2002 Dec;16(12):2366-78 [12454741.001]
  • [Cites] Blood. 2003 Jul 1;102(1):43-52 [12623843.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1232-40 [12714526.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3440-6 [12668650.001]
  • [Cites] Ann Hematol. 2004;83 Suppl 1:S45-8 [15124668.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2510-1 [15197216.001]
  • [Cites] Int J Hematol. 2004 Jun;79(5):495-500 [15239403.001]
  • [Cites] Blood. 1981 Oct;58(4):759-67 [7272506.001]
  • [Cites] Cancer Genet Cytogenet. 1984 Mar;11(3):332-50 [6704938.001]
  • [Cites] Blood. 1985 Jun;65(6):1364-72 [3857944.001]
  • [Cites] J Clin Oncol. 1986 Dec;4(12):1748-57 [3783201.001]
  • [Cites] Br J Haematol. 1989 May;72(1):45-53 [2736242.001]
  • [Cites] Blood. 1990 Sep 15;76(6):1083-91 [2400804.001]
  • [Cites] Leuk Res. 1992;16(1):43-6 [1732669.001]
  • [Cites] J Clin Oncol. 1993 Dec;11(12):2370-9 [8246025.001]
  • [Cites] Blood Rev. 1994 Mar;8(1):30-6 [8205008.001]
  • [Cites] Bone Marrow Transplant. 1995 Aug;16(2):203-8 [7581137.001]
  • [Cites] Br J Haematol. 1995 Sep;91(1):104-8 [7577615.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2079-88 [9058730.001]
  • [Cites] Blood. 1997 Apr 1;89(7):2578-85 [9116305.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2931-8 [9376573.001]
  • [Cites] Bone Marrow Transplant. 1997 Nov;20(9):737-43 [9384475.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1910-7 [9731047.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3128-35 [10506609.001]
  • [Cites] Ann Hematol. 2005 Jan;84(1):25-32 [15349754.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):790-7 [16418499.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1791-9 [16254134.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):963-71 [10694545.001]
  • (PMID = 17531775.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U19 AI029530-14; United States / NIAID NIH HHS / AI / U19 AI 29530; United States / NHLBI NIH HHS / HL / P01 HL070149; United States / NCI NIH HHS / CA / T32 CA009172; United States / NIAID NIH HHS / AI / AI029530-14; United States / NHLBI NIH HHS / HL / P01 HL 070149; United States / NIAID NIH HHS / AI / U19 AI029530
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS25237; NLM/ PMC2743535
  •  go-up   go-down


6. Godder KT, Henslee-Downey PJ, Mehta J, Park BS, Chiang KY, Abhyankar S, Lamb LS: Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant; 2007 Jun;39(12):751-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation.
  • Allogeneic stem cell transplantation (ASCT) has improved leukemia-free survival (LFS) in many but not all patients with acute leukemia.
  • This is an eight-year follow-up to our previous study showing a survival advantage to patients with an increased gammadelta T cells following ASCT. gammadelta T cell levels were collected prospectively in 153 patients (acute lymphoblastic leukemia (ALL) n = 77; acute myelogenous leukemia (AML) n = 76) undergoing partially mismatched related donor ASCT.
  • Median age was 22 years (1-59), and 62% of the patients were in relapse at transplant.
  • In conclusion, gammadelta T cells may facilitate a graft-versus-leukemia (GvL) effect, without causing GvHD.
  • Further evaluations of this effect may lead to specific immunotherapy for patients with refractory leukemia.
  • [MeSH-major] Bone Marrow Transplantation. Histocompatibility Testing. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Receptors, Antigen, T-Cell, gamma-delta / metabolism


7. Harned TM, Gaynon PS: Treating refractory leukemias in childhood, role of clofarabine. Ther Clin Risk Manag; 2008 Apr;4(2):327-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Approximately 4000 children and adolescents under the age of 20 years develop acute leukemia per year in the US.
  • Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer.
  • Therapy for relapsed ALL remains unsatisfactory, and the majority of relapse patients still succumb to leukemia.
  • Between one-third and one-half of patients with acute myelogenous leukemia (AML) relapse, and no standard therapy is recognized for patients with relapsed and/or refractory AML.
  • Novel therapeutic agents are needed to improve the cure rate for relapsed ALL and AML.
  • Phase I and II single-agent trials in children have shown that clofarabine is safe and active in both myeloid and lymphoid relapsed/refractory acute leukemias.

  • SciCrunch. DrugBank: Data: Chemical .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):34-8 [7743235.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jan;50(1):9-16 [17252564.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3030-7 [8674058.001]
  • [Cites] Cancer. 1997 Dec 15;80(12):2321-32 [9404710.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1387-95 [9529033.001]
  • [Cites] Br J Haematol. 1998 Jul;102(2):423-38 [9695956.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4072-9 [9834212.001]
  • [Cites] Mol Pharmacol. 1999 Mar;55(3):515-20 [10051535.001]
  • [Cites] Br J Haematol. 1999 Sep;106(4):851-9 [10519984.001]
  • [Cites] J Biol Chem. 1951 Oct;192(2):505-18 [14907641.001]
  • [Cites] Cancer Res. 1954 May;14(4):294-8 [13160953.001]
  • [Cites] Ann N Y Acad Sci. 1950 Jul 7;52(8):1318-35 [15433149.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S32-9 [15309512.001]
  • [Cites] Blood. 2005 Feb 1;105(3):940-7 [15486072.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Apr;55(4):361-8 [15723262.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3537-43 [11071652.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3142-53 [11408512.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3244-54 [11432892.001]
  • [Cites] Lancet. 2001 Oct 13;358(9289):1239-41 [11675066.001]
  • [Cites] Cancer Chemother Biol Response Modif. 2001;19:21-45 [11686015.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3580-9 [11705880.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1668-72 [12200679.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1167-73 [12637486.001]
  • [Cites] Blood. 2003 May 15;101(10):3868-71 [12543868.001]
  • [Cites] Br J Haematol. 2003 Jul;122(1):24-9 [12823342.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2940-7 [12885813.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2379-86 [12791647.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):396-405 [14616997.001]
  • [Cites] Leukemia. 2004 Mar;18(3):499-504 [14981525.001]
  • [Cites] Onkologie. 2004 Jun;27(3):269-72 [15249716.001]
  • [Cites] J Clin Pharmacol. 2004 Nov;44(11):1309-22 [15496649.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1191-8 [3114435.001]
  • [Cites] Cancer Res. 1991 May 1;51(9):2386-94 [1707752.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2970-4 [1348362.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4377-85 [14645428.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6335-42 [14695132.001]
  • [Cites] Blood. 2004 Feb 1;103(3):784-9 [14551141.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Cancer. 2005 May 15;103(10):1985-95 [15803490.001]
  • [Cites] Drug Metab Dispos. 2005 Jun;33(6):739-48 [15743978.001]
  • [Cites] Nat Rev Drug Discov. 2005 May;4(5):369-70 [15902772.001]
  • [Cites] Nat Rev Drug Discov. 2005 May;Suppl:S12-3 [15962525.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1183-8 [15886328.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7942-50 [16258094.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2030-42 [16304570.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2130-8 [16304572.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):579-87 [16351633.001]
  • [Cites] Best Pract Res Clin Haematol. 2006;19(2):311-20 [16516128.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1917-23 [16622268.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4961-7 [16493003.001]
  • [Cites] Blood. 2006 Jul 1;108(1):45-51 [16403905.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3150-6 [16717292.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):4011-7 [16818700.001]
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4499-506 [16983120.001]
  • [Cites] Nat Rev Drug Discov. 2006 Oct;5(10):855-63 [17016426.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2764-9 [16809615.001]
  • [Cites] Blood. 2007 Feb 1;109(3):926-35 [17003380.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Feb;7(2):113-8 [17288522.001]
  • [Cites] Leuk Lymphoma. 2007 Jan;48(1):1-2 [17325839.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2847-52 [7540950.001]
  • (PMID = 18728851.001).
  • [ISSN] 1176-6336
  • [Journal-full-title] Therapeutics and clinical risk management
  • [ISO-abbreviation] Ther Clin Risk Manag
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2504075
  • [Keywords] NOTNLM ; childhood / clofarabine / leukemia / pediatric / refractory
  •  go-up   go-down


8. Gu WY, Chen ZX, Hu SY, Zhu J, Wang ZL, Yan F, Wang W, Cen JN, Shen HL, Qian J: [Significance of dynamic detection of WT1 expression on monitoring minimal residual disease in leukemia patients following allogeneic bone marrow transplantation]. Zhonghua Yi Xue Za Zhi; 2005 Feb 23;85(7):444-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Significance of dynamic detection of WT1 expression on monitoring minimal residual disease in leukemia patients following allogeneic bone marrow transplantation].
  • OBJECTIVE: To investigate the significance of monitoring Wilms' tumor gene (WT1) expression level in bone marrow of leukemia patients following allogeneic bone marrow transplantation (allo-BMT).
  • METHODS: Real-time quantitative reverse transcription polymerase chain reaction method was established for measuring WT1 and GAPDH expression levels in bone marrow cells of 15 patients with leukemia, including a total of 111 specimens during the follow-up, and in 23 non-leukemia patients by using LightCycler.
  • RESULTS: The median expression levels of WT1(N) in 17 samples of newly diagnosed patients, 6 samples of relapsed patients, 88 samples from leukemia patient in complete remission and 23 samples of non-leukemic controls were 40.18 (5.48 to 510.27), 125.89 (34.50 to 273.95), 4.80 (0 to 56.96) and 1.47 (0 to 8.56) respectively.
  • Spearman Rho correlation analysis revealed that the correlation coefficient between the WT1(N) expression levels and BCR/ABL, AML/ETO, PML/RARalpha and MLL/AF17 fusion genes expression were 0.678 (P = 0.00), 0.677 (P = 0.00), 0.806 (P = 0.00) and 0.553 (P = 0.049) respectively.
  • A re-increment of WT1(N) expression level during follow-up could be detected 40 to 180 days earlier to hematological relapse.
  • CONCLUSION: The WT1 expression level of leukemia patients following allo-BMT measured by real time RT-PCR can be a useful tool for monitoring MRD and warning the clinical relapse during follow-up.
  • [MeSH-major] Bone Marrow Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism. Leukemia, Myeloid, Acute / metabolism. WT1 Proteins / biosynthesis


9. Lashkari A, Lowe T, Collisson E, Paquette R, Emmanouilides C, Territo M, Schiller G: Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or =60 years with acute myelogenous leukemia. Biol Blood Marrow Transplant; 2006 Apr;12(4):466-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or =60 years with acute myelogenous leukemia.
  • The optimal postremission treatment for elderly patients with acute myelogenous leukemia (AML) is presently unknown, but recent studies report the feasibility of autologous stem cell transplantation in this population.
  • To better understand the long-term outcome of autologous transplantation in AML patients > or =60 years of age, we evaluated high-dose chemoradiotherapy preparative conditioning followed by transplantation of peripheral blood progenitor cells procured after a single cycle of cytarabine-based consolidation chemotherapy as postremission therapy in 27 patients aged 60 to 71 years (median age, 65 years) with newly diagnosed AML in first complete remission (CR).
  • Seven patients are alive in continuous CR, 19 died from relapse, and 1 died as a result of treatment-related infection.
  • Leukemia-free survival and overall survival are 10.3 and 13.4 months, respectively.
  • Actuarial leukemia-free and overall survival at 3 years are 25% +/- 9% and 28% +/- 9%, respectively.
  • Our results demonstrate that autologous transplantation of peripheral blood progenitor cells is well tolerated and feasible for patients > or =60 years of age with AML in first CR.
  • [MeSH-major] Leukemia, Myeloid, Acute / mortality. Peripheral Blood Stem Cell Transplantation. Transplantation Conditioning

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16545730.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 04079A1RDZ / Cytarabine
  •  go-up   go-down


10. Karp JE, Smith BD, Gojo I, Lancet JE, Greer J, Klein M, Morris L, Levis MJ, Gore SD, Wright JJ, Garrett-Mayer E: Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res; 2008 May 15;14(10):3077-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.
  • PURPOSE: Acute myelogenous leukemia (AML) does not have a high cure rate, particularly in patients with poor-risk features.
  • Tipifarnib is an oral farnesyltransferase inhibitor with activity in AML.
  • We conducted a phase II trial of maintenance tipifarnib monotherapy for 48 adults with poor-risk AML in first CR.
  • RESULTS: Twenty (42%) patients completed 16 cycles, 24 (50%) were removed from study for relapse, and 4 (8%) discontinued drug prematurely for intolerance.
  • Comparison of CR durations for 25 patients who received two-cycle timed sequential therapy followed by tipifarnib maintenance with 23 historically similar patients who did not receive tipifarnib showed that tipifarnib was associated with DFS prolongation for patients with secondary AML and adverse cytogenetics.
  • CONCLUSIONS: This study suggests that some patients with poor-risk AML, including patients with secondary AML and adverse cytogenetics, may benefit from tipifarnib maintenance therapy.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Leukemia. 2007 Sep;21(9):1964-70 [17581608.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3361-9 [11369625.001]
  • [Cites] Blood. 2001 Aug 1;98(3):548-53 [11468148.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1302-11 [11520775.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1312-20 [11520776.001]
  • [Cites] Leuk Res. 2003 Apr;27(4):313-21 [12531222.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1692-7 [12411300.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):672-80 [12760285.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3880-9 [12920034.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4527-34 [12947010.001]
  • [Cites] Blood Rev. 2004 Mar;18(1):39-63 [14684148.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1287-92 [15051776.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1605-16 [15084693.001]
  • [Cites] Blood. 1989 Oct;74(5):1499-506 [2676014.001]
  • [Cites] Blood. 1992 Apr 15;79(8):1924-30 [1562720.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2952-61 [9376575.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):872-81 [9508168.001]
  • [Cites] Leukemia. 1999 Jun;13(6):843-9 [10360370.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1969-78 [15632409.001]
  • [Cites] Eur J Haematol. 2005 May;74(5):418-23 [15813916.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2480-9 [16735702.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1677-83 [16670265.001]
  • [Cites] Blood. 2007 Jan 15;109(2):431-48 [16960150.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1387-94 [17082323.001]
  • [Cites] Blood. 2007 May 15;109(10):4158-63 [17264294.001]
  • [Cites] J Clin Oncol. 2007 May 10;25(14):1908-15 [17488990.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Feb;14(1):251-67 [10680081.001]
  • (PMID = 18483374.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 69854; United States / NCI NIH HHS / CA / U01 CA069854-07; United States / NCI NIH HHS / CA / U01 CA069854; United States / NCI NIH HHS / CA / U01 CA70095; United States / NCI NIH HHS / CA / U01 CA070095
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinolones; 192185-72-1 / tipifarnib
  • [Other-IDs] NLM/ NIHMS281726; NLM/ PMC3074480
  •  go-up   go-down


11. Das-Gupta EP, Russell NH, Shaw BE, Pearce RM, Byrne JL: Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab. Biol Blood Marrow Transplant; 2007 Jun;13(6):724-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab.
  • The outcome of 55 patients who underwent matched unrelated donor (MUD) transplantation for acute myelogenous leukemia (AML) following a conditioning regimen of cyclophosphamide and total-body irradiation (TBI) with the addition of Alemtuzumab 10 mg/kg/day on days -5 to -1 is described.
  • Forty-one patients were transplanted in complete remission (CR) (20 in CR1, 20 in CR2, and 1 in CR3), and 14 were not in remission at the time of transplantation as they were refractory to chemotherapy either at induction or at relapse.
  • Grade II-IV acute GVHD occurred in only 2 patients.
  • The 5-year cumulative incidence of relapse was 36% for the whole group and 28% for patients in CR at transplantation.
  • These results support the use of Alemtuzumab for unrelated donor hematopoietic stem cell transplant (HSCT) for poor risk AML in CR1 and for relapsed AML in CR2.
  • The addition of Alemtuzumab is highly effective in preventing both rejection and severe acute and extensive chronic GVHD without an increased relapse risk.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antibodies, Neoplasm / administration & dosage. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Antibodies, Monoclonal, Humanized. Cause of Death. Cyclophosphamide / therapeutic use. Female. Graft Rejection / prevention & control. Graft vs Host Disease / prevention & control. Histocompatibility Testing. Humans. Longitudinal Studies. Male. Middle Aged. Myeloablative Agonists / therapeutic use. Survival Analysis. Tissue Donors. Treatment Outcome. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17531783.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Myeloablative Agonists; 3A189DH42V / alemtuzumab; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


12. Cammenga J, Horn S, Bergholz U, Sommer G, Besmer P, Fiedler W, Stocking C: Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate. Blood; 2005 Dec 1;106(12):3958-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate.
  • Multiple genetic alterations are required to induce acute myelogenous leukemia (AML).
  • Mutations in the extracellular domain of the KIT receptor are almost exclusively found in patients with AML carrying translocations or inversions affecting members of the core binding factor (CBF) gene family and correlate with a high risk of relapse.
  • Our data show that the addition of kinase inhibitors to conventional chemotherapy might be a new therapeutic option for CBF-AML expressing mutant KIT.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Core Binding Factors / genetics. Leukemia, Myeloid, Acute / genetics. Piperazines / pharmacology. Pyrimidines / pharmacology. Stem Cell Factor / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16081693.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Core Binding Factors; 0 / Piperazines; 0 / Pyrimidines; 0 / Stem Cell Factor; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


13. Davies SM, Wang D, Wang T, Arora M, Ringden O, Anasetti C, Pavletic S, Casper J, Macmillan ML, Sanders J, Wall D, Kernan NA: Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants. Biol Blood Marrow Transplant; 2009 Mar;15(3):360-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants.
  • Unrelated donor (URD) bone marrow transplantation (BMT) is an effective treatment for leukemia in children, but its success is threatened by graft-versus-host disease (GVHD) and relapse.
  • We analyzed outcomes of 638 myeloablative URD BMTs performed between 1990 and 2003 to treat acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia, or myelodysplastic syndrome MDS, using the Center for International Blood and Marrow Transplant Research (CIBMTR) database.
  • Overall, 27% of the recipients developed acute GVHD (aGVHD) grade III-IV; the risk was significantly higher in children receiving T cell-replete grafts compared with those receiving T cell-depleted grafts (odds ratio [OR] = 3.12; 95% confidence interval [CI] = 2.02 to 4.83; P < .0001).
  • Acute GVHD significantly reduced the risk of relapse in children with ALL (OR = 0.34; 95% CI = 0.13 to 0.86; P = .0052), but not in those with AML (OR = 0.58; 95% CI = 0.22 to 2.98; P = .26).
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Hematopoietic Stem Cell Transplantation / adverse effects. Humans. Leukemia / immunology. Male. Multivariate Analysis. Recurrence. Retrospective Studies. Risk Factors. Tissue Donors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stat Med. 2006 Mar 30;25(6):1015-34 [16435339.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2236-46 [10498594.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4576-83 [17785583.001]
  • [Cites] Semin Hematol. 1999 Oct;36(4 Suppl 7):95-103 [10595758.001]
  • [Cites] Clin Transpl. 1999;:121-7 [11038630.001]
  • [Cites] Blood Rev. 2000 Dec;14(4):190-204 [11124107.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(6):633-9 [11128814.001]
  • [Cites] Cancer. 2001 Jan 1;91(1 Suppl):274-8 [11148593.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1572-7 [11238093.001]
  • [Cites] Bone Marrow Transplant. 2001 Jan;27(1):35-43 [11244436.001]
  • [Cites] Bone Marrow Transplant. 2001 Apr;27(7):727-30 [11360113.001]
  • [Cites] Haematologica. 2001 May;86(5):451-6 [11410406.001]
  • [Cites] Bone Marrow Transplant. 2001 Jul;28(2):121-9 [11509929.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1695-700 [11535499.001]
  • [Cites] Transplantation. 2001 Sep 15;72(5):923-9 [11571460.001]
  • [Cites] Curr Opin Hematol. 2001 Nov;8(6):349-54 [11604574.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3505-12 [11739150.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1971-7 [11877268.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2002-8 [11877272.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Blood. 1990 Feb 1;75(3):555-62 [2297567.001]
  • [Cites] N Engl J Med. 1990 Feb 22;322(8):485-94 [2300120.001]
  • [Cites] Blood. 1990 Jun 15;75(12):2459-64 [2350582.001]
  • [Cites] Blood. 1993 Jan 1;81(1):249-53 [8417795.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1636-42 [7632974.001]
  • [Cites] Bone Marrow Transplant. 1995 May;15(5):663-8 [7670393.001]
  • [Cites] Br J Haematol. 1996 Apr;93(1):59-67 [8611476.001]
  • [Cites] Bone Marrow Transplant. 1996 Nov;18(5):891-7 [8932842.001]
  • [Cites] Blood Rev. 1996 Dec;10(4):215-9 [9012918.001]
  • [Cites] N Engl J Med. 1998 Apr 2;338(14):962-8 [9521984.001]
  • [Cites] Bone Marrow Transplant. 1998 Oct;22(8):755-61 [9827972.001]
  • [Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Aug;12(8):876-84 [16864058.001]
  • (PMID = 19203727.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS219377; NLM/ PMC3365559
  •  go-up   go-down


14. Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T, Maris MB, Agura ED, Chauncey TR, Wong RM, Forman SJ, Petersen FB, Wade JC, Epner E, Bruno B, Bethge WA, Curtin PT, Maloney DG, Blume KG, Storb RF: Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant; 2008 Feb;14(2):246-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the results of 148 patients (median age = 59 years old) with de novo MDS (n = 40), acute myelogenous leukemia (AML) after antecedent MDS/MPD (n = 49), treatment-related MDS (t-MDS) (n = 25), MPD (n = 27), and chronic myelomonocytic leukemia (CMML) (n = 7) who underwent allogeneic HCT using a conditioning regimen of low-dose total body irradiation (TBI) alone (200 cGy) on day 0 (n = 5) or with the addition of fludarabine (Flu) 30 mg/m(2)/day on days -4 to -2 (n = 143).
  • There was no significant difference in the incidence of acute (gr II-IV) and chronic extensive graft-versus-host disease (aGVHD, cGVHD) between the recipients of related and unrelated donor grafts.
  • With a median follow-up of 47 (range: 6-89) months, the 3-year relapse-free survival (RFS) and overall survival (OS) are both 27% for all patients, with a relapse incidence of 41%.
  • The 3-year RFS for the patients with de novo MDS, AML after antecedent MDS/MPD, t-MDS, MPD, and CMML were 22%, 20%, 29%, 37%, and 43%, respectively, and the 3-year OS was 20%, 23%, 27%, 43%, and 43%, respectively.
  • Factors associated with a lower risk of relapse were the development of extensive cGVHD and having a low risk or intermediate-1 risk International Prognostic Score for the de novo MDS patients.
  • Nonmyeloablative HCT confers remissions in patients who otherwise were not eligible for conventional HCT but for whom relapse is the leading cause of treatment failure.

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Blood Marrow Transplant. 2007 Apr;13(4):454-62 [17382251.001]
  • [Cites] Blood. 2006 Aug 1;108(3):836-46 [16597592.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2134-41 [11304765.001]
  • [Cites] Blood. 2002 Feb 1;99(3):840-9 [11806985.001]
  • [Cites] Br J Haematol. 2002 Jul;118(1):67-73 [12100129.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1997-2004 [12200358.001]
  • [Cites] Blood. 2002 Sep 15;100(6):2243-5 [12200391.001]
  • [Cites] Ann Hematol. 2003 Jun;82(6):336-42 [12728337.001]
  • [Cites] Bone Marrow Transplant. 2003 Jul;32(1):35-40 [12815476.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3060-5 [12915594.001]
  • [Cites] Blood. 2003 Sep 15;102(6):2021-30 [12791654.001]
  • [Cites] Blood. 2003 Oct 15;102(8):3052-9 [12842990.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3912-8 [12920019.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Dec;9(12):753-9 [14677114.001]
  • [Cites] Blood. 2004 Aug 1;104(3):857-64 [15073038.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1616-23 [15059843.001]
  • [Cites] Bone Marrow Transplant. 2004 Nov;34(9):807-13 [15354205.001]
  • [Cites] Transplantation. 1974 Oct;18(4):295-304 [4153799.001]
  • [Cites] Blood. 1996 Jul 1;88(1):358-65 [8704196.001]
  • [Cites] Blood. 1997 Apr 1;89(7):2578-85 [9116305.001]
  • [Cites] Bone Marrow Transplant. 1997 Nov;20(9):737-43 [9384475.001]
  • [Cites] Bone Marrow Transplant. 1998 Feb;21(3):255-61 [9489648.001]
  • [Cites] Haematologica. 1998 Jun;83(6):543-9 [9676028.001]
  • [Cites] Blood. 1999 May 1;93(9):2831-8 [10216077.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1810-4 [15459007.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1993-2003 [15774790.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Sep;11(9):713-20 [16125642.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4381-8 [16144801.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Apr;12(4):454-65 [16545729.001]
  • [Cites] Leukemia. 2006 Jan;20(1):128-35 [16270037.001]
  • [Cites] Bone Marrow Transplant. 2006 Jun;37(11):1003-8 [16604096.001]
  • [Cites] Br J Haematol. 2000 Sep;110(3):620-30 [10997974.001]
  • (PMID = 18215785.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA049605-14; United States / NCI NIH HHS / CA / CA18029; United States / NHLBI NIH HHS / HL / HL036444-27; United States / NCI NIH HHS / CA / K23 CA092058-01; United States / NHLBI NIH HHS / HL / HL36444; United States / NCI NIH HHS / CA / P30 CA015704-31; United States / NCI NIH HHS / CA / P01 CA018029; United States / NCI NIH HHS / CA / P30 CA015704; United States / NCI NIH HHS / CA / CA78902; United States / NCI NIH HHS / CA / CA92058; United States / NCI NIH HHS / CA / CA092058-01; United States / NCI NIH HHS / CA / K23 CA092058; United States / NCI NIH HHS / CA / P01 CA018029-250002; United States / NCI NIH HHS / CA / CA049605-14; United States / NCI NIH HHS / CA / P01 CA018029-270047; United States / NCI NIH HHS / CA / CA15704; United States / NCI NIH HHS / CA / P01 CA078902-09; United States / NCI NIH HHS / CA / CA018029-270047; United States / NCI NIH HHS / CA / CA078902-09; United States / NHLBI NIH HHS / HL / P01 HL036444-27; United States / NCI NIH HHS / CA / CA018029-250002; United States / NHLBI NIH HHS / HL / P01 HL036444; United States / NCI NIH HHS / CA / P01 CA078902; United States / NCI NIH HHS / CA / P01-CA 49605; United States / NCI NIH HHS / CA / CA015704-31; United States / NCI NIH HHS / CA / P01 CA049605
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  • [Other-IDs] NLM/ NIHMS39955; NLM/ PMC2259225
  •  go-up   go-down


15. Oshima K, Kanda Y, Yamashita T, Takahashi S, Mori T, Nakaseko C, Fujimaki K, Yokota A, Fujisawa S, Matsushima T, Fujita H, Sakura T, Okamoto S, Maruta A, Sakamaki H, Kanto Study Group for Cell Therapy: Central nervous system relapse of leukemia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant; 2008 Oct;14(10):1100-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system relapse of leukemia after allogeneic hematopoietic stem cell transplantation.
  • Little information is available regarding central nervous system (CNS) relapse of adult leukemia after allogeneic hematopoietic stem cell transplantation (HSCT).
  • Therefore, we reviewed the data of 1226 patients with acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myelogenous leukemia (CML) who received first allogeneic HSCT between 1994 and 2004, using the database of the Kanto Study Group for Cell Therapy (KSGCT), and analyzed the incidence, risk factors, and outcome of patients with CNS relapse.
  • Twenty-nine patients developed CNS relapse at a median of 296 (9-1677) days after HSCT with a cumulative incidence of 2.3%.
  • Independent significant factors associated with CNS relapse included ALL as the underlying diagnosis (relative risk [RR] = 9.55, 95% confidence interval [CI] = 1.26-72.2, P = .029), nonremission at HSCT (RR = 2.30, 95% CI = 1.03-5.15, P = .042), the history of CNS invasion before HSCT (RR = 5.62, 95% CI = 2.62-12.0, P = 9.2 x 10(-6)), and the prophylactic intrathecal chemotherapy after HSCT (RR = 2.57, 95% CI = 1.21-5.46, P = .014).
  • The 3-year overall survival (OS) after CNS relapse was 18%.
  • In 7 of 29 patients with CNS relapse, leukemia was observed only in CNS.
  • Three of 7 patients were alive without systemic relapse, resulting in 3-year survival after CNS relapse of 46%.
  • Although the outcome of patients with CNS relapse was generally poor, long-term disease-free survival could be achieved in some patients.
  • [MeSH-major] Central Nervous System Neoplasms / etiology. Hematopoietic Stem Cell Transplantation. Leukemia / pathology. Leukemia / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Humans. Incidence. Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Leukemia, Myeloid, Acute. Leukemic Infiltration. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma. Recurrence. Retrospective Studies. Risk Factors. Survival Rate. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18804039.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Lee SE, Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, Min CK, Lee S, Cho SG, Kim DW, Lee JW, Park CW, Kim CC: Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities. Int J Hematol; 2010 Sep;92(2):342-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities.
  • To define the role of RIC in AML with old age (>or=55 years) and/or co-morbidities (HCT-CI scores >or=2), we analyzed patients who received allogeneic stem cell transplantation (SCT) with Flu/Bu/TBI 400 cGy/+/-antithymocyte globulin (ATG) conditioning regimen.
  • At a median follow-up of 18 months (range 4-40) for survivors, the estimated 2-year rates of overall survival, event-free survival, transplantation-related mortality, and relapse were 66, 63, 26, and 16%, respectively.
  • The incidence of acute (grades II-IV) and chronic GVHD by NIH consensus criteria was 34.4 and 62.5%.
  • This study suggests that the Flu/Bu/TBI 400 cGy or Flu/Bu/TBI 400 cGy/ATG-based conditioning regimens maybe a feasible therapeutic approach for AML with old age and/or co-morbidities.
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Antineoplastic Agents. Antineoplastic Agents, Alkylating. Comorbidity. Female. Humans. Leukemia, Myeloid, Acute. Male. Middle Aged. Survival Analysis. Transplantation Conditioning / methods. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Blood Marrow Transplant. 2010 Sep;16(9):1315-23 [20353831.001]
  • [Cites] Blood. 2006 May 1;107(9):3463-8 [16384925.001]
  • [Cites] Br J Haematol. 2010 Apr;149(1):101-10 [20067562.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Jun;15(6):704-17 [19450755.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):444-53 [16344316.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 May;12(5):573-84 [16635793.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4606-13 [17873123.001]
  • [Cites] Bone Marrow Transplant. 2007 Feb;39(4):193-9 [17220905.001]
  • [Cites] Leukemia. 2007 Jul;21(7):1357-62 [17508002.001]
  • [Cites] Am J Hematol. 2010 Apr;85(4):243-8 [20162540.001]
  • [Cites] Int J Hematol. 2007 Apr;85(3):256-63 [17483064.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56 [16338616.001]
  • [Cites] Biol Blood Marrow Transplant. 2002;8(9):468-76 [12374451.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:384-9 [16304408.001]
  • [Cites] Bone Marrow Transplant. 2005 Oct;36(8):667-74 [16113674.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2072-7 [12357359.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2304-12 [16193083.001]
  • [Cites] Bone Marrow Transplant. 2008 Mar;41(5):415-23 [18209726.001]
  • [Cites] Curr Opin Oncol. 2007 Nov;19(6):660-6 [17906468.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Jul;13(7):814-21 [17580259.001]
  • [Cites] Blood. 2001 Nov 15;98(10):2942-7 [11698275.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):544-51 [17141976.001]
  • (PMID = 20694843.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine
  •  go-up   go-down


17. Navarro WH, Agovi MA, Logan BR, Ballen K, Bolwell BJ, Frangoul H, Gupta V, Hahn T, Ho VT, Juckett M, Lazarus HM, Litzow MR, Liesveld JL, Moreb JS, Marks DI, McCarthy PL, Pasquini MC, Rizzo JD: Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults. Biol Blood Marrow Transplant; 2010 Oct;16(10):1442-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults.
  • We compared outcomes by body mass index (BMI) for adult patients with acute myelogenous leukemia (AML) who underwent autologous (auto, n = 373), related donor (RD, n = 2041), or unrelated donor (URD, n = 1801) allogeneic myeloablative hematopoietic cell transplantation (HCT) using bone marrow or peripheral blood stem cells reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) from 1995 to 2004.
  • Overweight and obese patients enjoyed a modest decrease in relapse incidence, although this did not translate into a survival benefit.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • [Cites] JAMA. 2007 Nov 7;298(17):2028-37 [17986696.001]
  • [Cites] Cent Eur J Public Health. 2006 Dec;14(4):151-9 [17243492.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):748-58 [18541193.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Nov;93(11 Suppl 1):S9-30 [18987276.001]
  • [Cites] Anadolu Kardiyol Derg. 2008 Dec;8(6):401-6 [19103534.001]
  • [Cites] Ann Acad Med Singapore. 2009 Jan;38(1):57-9 [19221672.001]
  • [Cites] BMC Public Health. 2009;9:88 [19320986.001]
  • [Cites] JAMA. 2009 Jun 10;301(22):2349-61 [19509382.001]
  • [Cites] Angiology. 2010 Feb-Mar;61(1):42-8 [19398424.001]
  • [Cites] Leuk Lymphoma. 1997 May;25(5-6):487-91 [9250819.001]
  • [Cites] Obes Res. 1998 Sep;6 Suppl 2:51S-209S [9813653.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2912-9 [15994282.001]
  • [Cites] JAMA. 2006 Apr 5;295(13):1549-55 [16595758.001]
  • [Cites] World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253 [11234459.001]
  • [Cites] Bone Marrow Transplant. 2001 Aug;28(4):365-7 [11571508.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1309-10 [11965278.001]
  • [Cites] Transplantation. 1974 Oct;18(4):295-304 [4153799.001]
  • [Cites] Am J Med. 1980 Aug;69(2):204-17 [6996481.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 May;12(5):541-51 [16635789.001]
  • [Cites] Obes Rev. 2008 Mar;9 Suppl 1:14-21 [18307694.001]
  • (PMID = 20412867.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / U01 HL069294; United States / NCI NIH HHS / CA / U24 CA076518; United States / NHLBI NIH HHS / HL / 5U01HL069294; United States / NCI NIH HHS / CA / U24-CA76518
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myeloablative Agonists
  • [Other-IDs] NLM/ NIHMS210175; NLM/ PMC2933950
  •  go-up   go-down


18. Al-Ali H, Cross M, Lange T, Freund M, Dölken G, Niederwieser D: Low-dose total body irradiation-based regimens as a preparative regimen for allogeneic haematopoietic cell transplantation in acute myelogenous leukaemia. Curr Opin Oncol; 2009 Jun;21 Suppl 1:S17-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose total body irradiation-based regimens as a preparative regimen for allogeneic haematopoietic cell transplantation in acute myelogenous leukaemia.
  • Although much progress has been made in understanding the molecular basis of acute myeloid leukaemia (AML), this has not yet led to major improvements in the overall survival of patients.
  • In particular, the treatment of elderly patients with AML remains one of the major challenges in haematology.
  • Despite increases in complete remission rates, relapse remains a major obstacle and the major determinant of overall survival.
  • Allogeneic stem cell transplantation (SCT) is the most efficient antileukaemic treatment for patients with AML, but eligibility for the treatment was confined for a long time to younger patients.
  • TRM does not currently exceed 10-12% in related and 20% in unrelated SCT even in patients up to the age of 75 years, so that relapse after transplantation remains the major problem.
  • A number of strategies for decreasing relapse rates has been developed.
  • This has led to decreases in the relapse rate over the past few years.
  • Randomized studies are now being initiated to define the role of SCT in the treatment of elderly patients with AML.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / radiotherapy. Transplantation Conditioning / methods. Whole-Body Irradiation / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Chimerism. Combined Modality Therapy. Graft Rejection. Graft vs Leukemia Effect. Humans. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19561407.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Kornblau SM, Qiu YH, Bekele BN, Cade JS, Zhou X, Harris D, Jackson CE, Estrov Z, Andreeff M: Studying the right cell in acute myelogenous leukemia: dynamic changes of apoptosis and signal transduction pathway protein expression in chemotherapy resistant ex-vivo selected "survivor cells". Cell Cycle; 2006 Dec;5(23):2769-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Studying the right cell in acute myelogenous leukemia: dynamic changes of apoptosis and signal transduction pathway protein expression in chemotherapy resistant ex-vivo selected "survivor cells".
  • We hypothesized that studying protein expression in cells surviving in vitro chemotherapy ("survivor cells", SV), could provide more important insight into the biology of drug-resistant AML cells than analysis of the bulk population of leukemic cells.
  • Leukemia-enriched samples from 79 patients with new or relapsed AML were cultured for four days +/- cytarabine (5-10 microM).
  • The patterns of change were highly predictive of remission attainment, relapse, and survival in univariate and multivariate analysis.
  • Analysis of SV cells may be more informative than analysis of the bulk population of leukemia cells.
  • [MeSH-major] Apoptosis. Drug Resistance, Neoplasm. Leukemia, Myeloid, Acute / pathology. Leukemia, Myeloid, Acute / therapy. Neoplasm Proteins / metabolism. Signal Transduction

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17172852.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Neoplasm Proteins
  •  go-up   go-down


20. Lipton J, Joffe S, Ullrich NJ: CNS relapse of acute myelogenous leukemia masquerading as pseudotumor cerebri. Pediatr Neurol; 2008 Nov;39(5):355-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS relapse of acute myelogenous leukemia masquerading as pseudotumor cerebri.
  • An 18-year-old man in remission from acute myelogenous leukemia 3 years after a bone marrow transplant presented with signs of pseudotumor cerebri, including headache, visual changes, and papilledema.
  • He was diagnosed with an isolated central nervous system relapse of acute myeloid leukemia.
  • Although the precise etiology remains elusive, this case demonstrates that pseudotumor cerebri must remain within the differential diagnosis after other complications are excluded, particularly in persons with underlying hematologic malignancies.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / diagnosis. Pseudotumor Cerebri / diagnosis. Pseudotumor Cerebri / etiology
  • [MeSH-minor] Adolescent. Biopsy. Diagnosis, Differential. Humans. Male. Recurrence


21. Petersen WC, Schlis KD, Braverman RS, Carlson I, Liang X, Wang M: Pseudohypopyon: Extramedullary relapse of acute myelogenous leukemia with poor prognosis. Pediatr Blood Cancer; 2009 Jul;52(7):885-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudohypopyon: Extramedullary relapse of acute myelogenous leukemia with poor prognosis.
  • She was diagnosed with acute myelogenous leukemia.
  • Towards the end of her second course of induction she developed pseudohypopyon in each eye on consecutive days, heralding a central nervous system relapse.
  • [MeSH-major] Anterior Chamber / pathology. Eye Diseases / diagnosis. Leukemia, Myelomonocytic, Acute / diagnosis. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Cytarabine / therapeutic use. Female. Humans. Infant. Injections, Spinal. Prognosis. Suppuration / diagnosis

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Eye Diseases.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 19090546.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  •  go-up   go-down


22. Guzman ML, Rossi RM, Karnischky L, Li X, Peterson DR, Howard DS, Jordan CT: The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood; 2005 Jun 1;105(11):4163-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells.
  • Recent studies have described malignant stem cells as central to the initiation, growth, and potential relapse of acute and chronic myelogenous leukemia (AML and CML).
  • Because of their important role in pathogenesis, rare and biologically distinct leukemia stem cells (LSCs) represent a critical target for therapeutic intervention.
  • The present studies demonstrate that parthenolide (PTL), a naturally occurring small molecule, induces robust apoptosis in primary human AML cells and blast crisis CML (bcCML) cells while sparing normal hematopoietic cells.
  • Furthermore, analysis of progenitor cells using in vitro colony assays, as well as stem cells using the nonobese diabetic/severe combined immunodeficient (NOD/SCID) xenograft model, show that PTL also preferentially targets AML progenitor and stem cell populations.
  • Notably, in comparison to the standard chemotherapy drug cytosine arabinoside (Ara-C), PTL is much more specific to leukemia cells.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4912-8 [15256463.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] FEBS Lett. 1997 Jan 27;402(1):85-90 [9013864.001]
  • [Cites] Blood. 1997 May 1;89(9):3104-12 [9129012.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4325-35 [9834239.001]
  • [Cites] Planta Med. 1999 Mar;65(2):126-9 [10193202.001]
  • [Cites] Carcinogenesis. 2004 Nov;25(11):2191-9 [15256485.001]
  • [Cites] Nat Prod Rep. 1995 Jun;12(3):271-6 [7792073.001]
  • [Cites] J Immunol. 1999 Nov 15;163(10):5617-23 [10553091.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jan 7;267(1):329-33 [10623619.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4844-9 [10781090.001]
  • [Cites] Exp Hematol. 2000 Jun;28(6):660-71 [10880752.001]
  • [Cites] Gene Ther. 2000 Jul;7(14):1234-7 [10918492.001]
  • [Cites] Oncogene. 2000 Aug 24;19(36):4159-69 [10962577.001]
  • [Cites] Leukemia. 2000 Oct;14(10):1777-84 [11021753.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2177-9 [11264190.001]
  • [Cites] J Biol Chem. 2001 Apr 13;276(15):12076-83 [11278531.001]
  • [Cites] Chem Biol. 2001 Aug;8(8):759-66 [11514225.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Sep 21;287(2):522-9 [11554760.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2301-7 [11588023.001]
  • [Cites] J Biol Chem. 2001 Oct 26;276(43):39713-20 [11500489.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7367-72 [12032289.001]
  • [Cites] J Biol Chem. 2002 Oct 11;277(41):38954-64 [12151389.001]
  • [Cites] J Lipid Res. 2002 Nov;43(11):1818-28 [12401880.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16220-5 [12451177.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3142-9 [12468427.001]
  • [Cites] Exp Mol Med. 2003 Aug 31;35(4):290-300 [14508070.001]
  • [Cites] J Dent Res. 2003 Oct;82(10):802-6 [14514760.001]
  • [Cites] Lab Invest. 2003 Oct;83(10):1529-39 [14563954.001]
  • [Cites] Cancer Control. 2004 Mar-Apr;11(2):97-104 [15024346.001]
  • [Cites] Invest New Drugs. 2004 Aug;22(3):299-305 [15122077.001]
  • [Cites] Cancer Lett. 2004 May 28;208(2):143-53 [15142672.001]
  • [Cites] Ann Oncol. 2004 Jun;15(6):885-90 [15151944.001]
  • [Cites] Life Sci. 2004 Jul 2;75(7):841-56 [15183076.001]
  • [Cites] Nat Immunol. 2004 Jul;5(7):738-43 [15170211.001]
  • [Cites] Oncogene. 2004 Sep 23;23(44):7330-44 [15286701.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1699-704 [15343345.001]
  • [Cites] J Pharm Sci. 1973 Feb;62(2):345 [4686424.001]
  • [Cites] Mol Pharmacol. 1981 Jan;19(1):97-102 [7207466.001]
  • [Cites] J Exp Med. 1992 Jun 1;175(6):1501-9 [1375263.001]
  • [Cites] Carcinogenesis. 2004 Aug;25(8):1449-58 [15033901.001]
  • (PMID = 15687234.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01-CA90446
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Lactones; 0 / NF-kappa B; 0 / Reactive Oxygen Species; 0 / Sesquiterpenes; 0 / Tumor Suppressor Protein p53; 2RDB26I5ZB / parthenolide
  • [Other-IDs] NLM/ PMC1895029
  •  go-up   go-down


23. Bacher U, Haferlach T, Alpermann T, Zenger M, Kröger N, Beelen DW, Kern W, Schnittger S, Haferlach C: Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML. Biol Blood Marrow Transplant; 2010 Dec;16(12):1649-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML.
  • Relapse of acute myelogenous leukemia has been associated with clonal cytogenetic evolution, but no study focused specifically on relapse after allogeneic hematopoietic stem cell transplantation (HSCT).
  • We compared karyotypes in 160 patients at both diagnosis and relapse either after allo-HSCT (n = 26) or standard chemotherapy (n = 134) using chromosome banding analysis combined with fluorescein in situ hybridization.
  • At diagnosis, aberrant karyotypes were more frequent in the HSCT than in the chemotherapy cohort (16 of 26; 61.5% versus 63 of 134; 47.0%).
  • Differences in the karyotypes between diagnosis and relapse were more frequent in the allo-cohort (14 of 26; 53.8% versus 49 of 134; 36.6%) than in the conventional cohort (n.s.
  • The mean number of cytogenetic alterations per patient was increasing from 2.0 at diagnosis to 4.0 at relapse in the allo-cohort, in the conventionally treated patients from 0.9 to 1.3 (both P < .001).
  • Thus, higher frequencies of clonal evolution and increasing cytogenetic complexity were observed in the stem cell recipients probably related to the more unfavorable cytogenetic profiles already depicted at diagnosis.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / pathology. Leukemia, Myeloid, Acute / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20558312.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Valencia A, Román-Gómez J, Cervera J, Such E, Barragán E, Bolufer P, Moscardó F, Sanz GF, Sanz MA: Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia. Leukemia; 2009 Sep;23(9):1658-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia.
  • Activation of the Wnt signaling pathway has been implicated recently in the pathogenesis of leukemia.
  • We studied the function of epigenetic regulation of the Wnt pathway and its prognostic relevance in acute myelogenous leukemia (AML).
  • Aberrant methylation of Wnt antagonists was detected in four AML cell lines and in up to 64% of AML marrow samples.
  • In a subgroup of patients 60 years and younger with newly diagnosed AML and intermediate-risk cytogenetics, abnormal methylation of Wnt antagonists was associated with decreased 4-year relapse-free survival (28 vs 61%, respectively, P=0.03).
  • Our results indicate a function of the epigenetic regulation of the Wnt pathway in predicting relapse in a subgroup of AML patients.
  • [MeSH-major] DNA Methylation. Epigenesis, Genetic. Leukemia, Myeloid, Acute / genetics. Signal Transduction. Wnt Proteins / antagonists & inhibitors

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19387464.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DKK1 protein, human; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / SFRP2 protein, human; 0 / Wnt Proteins; 776B62CQ27 / decitabine; EC 2.7.11.1 / ATR protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; M801H13NRU / Azacitidine
  •  go-up   go-down


25. Bhatla D, Gerbing RB, Alonzo TA, Mehta PA, Deal K, Elliott J, Meshinchi S, Geiger H, Perentesis JP, Lange BJ, Davies SM, Children's Oncology Group: DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group. Leukemia; 2008 Feb;22(2):265-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group.
  • Polymorphisms of DNA repair genes RAD51 and XRCC3 increase susceptibility to acute myeloid leukemia (AML) in adults, an effect enhanced by deletion of the glutathione-S-transferase M1 (GSTM1) gene.
  • In this study, we genotyped 452 children with de novo AML treated on CCG protocols 2941 and 2961 and compared genotype frequencies with those of normal blood donors, and analyzed the impact of genotype on outcome of therapy.
  • XRCC3 Thr241Met, RAD51 G135C and GSTM1 genotypes did not increase susceptibility to AML when assessed singly.
  • In contrast, when XRCC3 and RAD51 genotypes were examined together a significant increase in susceptibility to AML was seen in children with variant alleles.
  • Improved survival was due to reduced relapse in the heterozygous children, and this effect was most marked in children randomized to therapy likely to generate DNA double-strand breaks (etoposide, daunomycin), compared with anti-metabolite (fludarabine, cytarabine) based therapy.
  • In contrast, RAD51 G135C and the GSTM1 deletion polymorphism did not influence outcome of AML therapy in our study population.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Sep 1;98(5):1312-20 [11520776.001]
  • [Cites] EMBO J. 2004 Jan 28;23(2):439-49 [14726957.001]
  • [Cites] EMBO J. 2004 Feb 11;23(3):670-80 [14749735.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2675-80 [15102670.001]
  • [Cites] J Biol Chem. 2004 May 28;279(22):23250-4 [15037616.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):801-7 [15159313.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5560-3 [15313891.001]
  • [Cites] Mutat Res. 2004 Nov 22;556(1-2):169-81 [15491645.001]
  • [Cites] Cell. 1996 Nov 15;87(4):757-66 [8929543.001]
  • [Cites] EMBO J. 1998 Jan 15;17(2):598-608 [9430650.001]
  • [Cites] Mol Cell. 1998 May;1(6):783-93 [9660962.001]
  • [Cites] J Biol Chem. 1998 Aug 21;273(34):21482-8 [9705276.001]
  • [Cites] Carcinogenesis. 2004 Dec;25(12):2433-41 [15333465.001]
  • [Cites] Mutat Res. 2005 Feb 15;570(1):105-17 [15680408.001]
  • [Cites] Int J Cancer. 2005 Nov 20;117(4):611-8 [15924337.001]
  • [Cites] Laryngoscope. 2005 Dec;115(12):2221-31 [16369171.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):45-54 [16369571.001]
  • [Cites] Eur J Gynaecol Oncol. 2005;26(6):589-98 [16398215.001]
  • [Cites] World J Gastroenterol. 2005 Nov 14;11(42):6593-600 [16425350.001]
  • [Cites] Hum Mol Genet. 2006 Apr 1;15(7):1217-24 [16505003.001]
  • [Cites] Blood. 2006 Jul 1;108(1):74-80 [16537811.001]
  • [Cites] DNA Cell Biol. 2006 Jul;25(7):406-11 [16848682.001]
  • [Cites] J Clin Oncol. 2006 Aug 10;24(23):3799-808 [16896009.001]
  • [Cites] Eur J Hum Genet. 2006 Oct;14(10):1136-44 [16791138.001]
  • [Cites] Cancer Lett. 2006 Sep 8;241(1):142-9 [16343742.001]
  • [Cites] Mutat Res. 2007 Mar 5;627(2):146-57 [17158087.001]
  • [Cites] J Biol Chem. 2000 Jun 2;275(22):16443-9 [10749867.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Jun;9(6):563-6 [10868689.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5612-6 [11059748.001]
  • [Cites] Nat Genet. 2001 Mar;27(3):247-54 [11242102.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1279-87 [11230469.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3232-6 [11248061.001]
  • [Cites] Int J Cancer. 2001 May 15;92(4):562-7 [11304692.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 8;98(10):5538-43 [11331762.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8440-6 [11459987.001]
  • [Cites] Carcinogenesis. 2001 Sep;22(9):1437-45 [11532866.001]
  • [Cites] Hum Mol Genet. 2002 Jun 1;11(12):1399-407 [12023982.001]
  • [Cites] Oncogene. 2002 Jun 13;21(26):4176-80 [12037675.001]
  • [Cites] Nucleic Acids Res. 2002 Jul 1;30(13):2862-70 [12087170.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1513-30 [12496039.001]
  • [Cites] Mol Cell. 2003 Apr;11(4):1109-17 [12718895.001]
  • [Cites] Environ Health Perspect. 2003 Nov;111(15):1843-50 [14630517.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):150-6 [14701777.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):411-7 [14716779.001]
  • (PMID = 18033323.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA10262-01; United States / NCI NIH HHS / CA / R01 CA093552-01; United States / NCI NIH HHS / CA / CA 98543; United States / NCI NIH HHS / CA / R01 CA114563-01; United States / NCI NIH HHS / CA / R01CA93552-01; United States / NCI NIH HHS / CA / R01 CA093552; United States / NCI NIH HHS / CA / R01 CA114563; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA093552-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA-Binding Proteins; 0 / X-ray repair cross complementing protein 3; EC 2.7.7.- / Rad51 Recombinase
  • [Other-IDs] NLM/ NIHMS210453; NLM/ PMC2914507
  •  go-up   go-down


26. Kobayashi R, Tawa A, Hanada R, Horibe K, Tsuchida M, Tsukimoto I, Japanese childhood AML cooperative study group: Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia. Pediatr Blood Cancer; 2007 Apr;48(4):393-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia.
  • BACKGROUND: Extramedullary infiltration (EMI) is an occasional clinical symptom in childhood acute myelogenous leukemia (AML), but there is considerable controversy regarding the prognostic significance of EMI in AML.
  • PROCEDURE: We evaluated the frequency and prognostic significance of EMI at diagnosis of AML in children.
  • RESULTS: Of 240 cases of de novo AML excluding children with Down syndrome and acute promyelocytic leukemia, 56 (23.3%) showed EMI at diagnosis.
  • A detailed analysis showed that patients with EMI with a WBC count at diagnosis of over 100 x 10(9)/L or infiltration into the central nervous system are likely to have a poor prognosis.
  • CONCLUSIONS: CNS leukemia and EMI together with a WBC count of >100 x 10(9)/L at diagnosis of AML are high risk factors for relapse, and alternative treatment approaches for patients with these characteristics should be explored.
  • [MeSH-major] Leukemia, Myeloid / pathology. Leukemic Infiltration / epidemiology. Sarcoma, Myeloid / epidemiology
  • [MeSH-minor] Acute Disease. Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone and Bones / pathology. Central Nervous System / pathology. Child. Child, Preschool. Cytarabine / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Follow-Up Studies. Gingiva / pathology. Humans. Hydrocortisone / administration & dosage. Idarubicin / administration & dosage. Infant. Infant, Newborn. Japan / epidemiology. Kaplan-Meier Estimate. Male. Methotrexate / administration & dosage. Orbit / pathology. Prognosis. Remission Induction. Skin / pathology. Testis / pathology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550530.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate; ZRP63D75JW / Idarubicin
  •  go-up   go-down


27. Kornblit B, Masmas T, Madsen HO, Ryder LP, Svejgaard A, Jakobsen B, Sengeløv H, Olesen G, Heilmann C, Dickmeiss E, Petersen SL, Vindeløv L: Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants. Bone Marrow Transplant; 2008 May;41(10):851-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analysed the outcome and hospitalization requirements of the first 100 patients (Hodgkin's disease (HD), N=13; multiple myeloma (MM), N=14; CLL, N=12; non-Hodgkin's lymphoma (NHL), N=17; myelodysplastic syndrome (MDS), N=18; AML, N=24 and CML, N=2) treated in Denmark with haematopoietic cell transplantation after non-myeloablative conditioning with TBI 2 Gy+/-fludarabine.
  • The cumulative incidence of acute GVHD grade II-IV and extensive chronic GVHD was 67 and 49%.
  • After a median follow-up of 534 days, the overall survival, PFS, relapse-related mortality and treatment-related mortality were 59, 50, 25 and 17%, respectively.
  • Patients with CLL, NHL, AML and MDS with <5% blasts at any time had a favourable outcome with a PFS of 61-71%.
  • [MeSH-minor] Adult. Aged. Denmark / epidemiology. Female. Graft vs Host Disease / epidemiology. Hodgkin Disease / therapy. Hospitalization / statistics & numerical data. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Myeloid, Acute / therapy. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Multiple Myeloma / therapy. Myelodysplastic Syndromes / therapy. Outpatient Clinics, Hospital / utilization. Treatment Outcome. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246114.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


28. Matheny CJ, Speck ME, Cushing PR, Zhou Y, Corpora T, Regan M, Newman M, Roudaia L, Speck CL, Gu TL, Griffey SM, Bushweller JH, Speck NA: Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles. EMBO J; 2007 Feb 21;26(4):1163-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Monoallelic RUNX1 mutations cause familial platelet disorder with predisposition for acute myelogenous leukemia (FPD/AML).
  • Sporadic mono- and biallelic mutations are found at high frequencies in AML M0, in radiation-associated and therapy-related myelodysplastic syndrome and AML, and in isolated cases of AML M2, M5a, M3 relapse, and chronic myelogenous leukemia in blast phase.

  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • COS Scholar Universe. author profiles.
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - B6.129S-Runx1<tm1Spe>/J (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Biotechnol. 2002 Jan;20(1):87-90 [11753368.001]
  • [Cites] Biochemistry. 2005 Nov 15;44(45):14907-19 [16274238.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):68-76 [11900253.001]
  • [Cites] Br J Haematol. 2002 Jun;117(4):878-81 [12060124.001]
  • [Cites] Am J Hum Genet. 2002 Oct;71(4):724-38 [12196916.001]
  • [Cites] Blood. 2003 Jan 15;101(2):673-80 [12393679.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1277-83 [12393381.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):33088-96 [12807882.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):33097-104 [12807883.001]
  • [Cites] J Biol Chem. 2004 Feb 13;279(7):5772-80 [14645226.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):9176-89 [14660575.001]
  • [Cites] Mol Cell. 2006 Jun 23;22(6):741-53 [16793544.001]
  • [Cites] Blood. 2007 Jan 1;109(1):11-21 [16940420.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2316-24 [14615365.001]
  • [Cites] Nat Biotechnol. 2004 Apr;22(4):445-9 [14990965.001]
  • [Cites] Oncogene. 2004 May 24;23(24):4284-96 [15156185.001]
  • [Cites] Hum Mol Genet. 1999 Nov;8(12):2311-6 [10545612.001]
  • [Cites] Structure. 1999 Oct 15;7(10):1247-56 [10545320.001]
  • [Cites] Dev Biol. 2000 Apr 1;220(1):27-36 [10720428.001]
  • [Cites] FEBS Lett. 2000 Mar 24;470(2):125-30 [10734220.001]
  • [Cites] FEBS Lett. 2000 Mar 24;470(2):167-72 [10734228.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2862-9 [11023523.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3154-60 [11049997.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):39579-88 [10984496.001]
  • [Cites] Cell. 2001 Mar 9;104(5):755-67 [11257229.001]
  • [Cites] Nat Struct Biol. 2001 Apr;8(4):371-8 [11276260.001]
  • [Cites] J Mol Biol. 2001 Apr 27;308(2):191-203 [11327761.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2856-8 [11675361.001]
  • [Cites] Science. 1990 Oct 5;250(4977):113-6 [2218501.001]
  • [Cites] Cell Growth Differ. 1990 Dec;1(12):571-80 [2288874.001]
  • [Cites] Science. 1995 Mar 10;267(5203):1498-502 [7878469.001]
  • [Cites] Nat Struct Biol. 1994 Dec;1(12):877-90 [7773777.001]
  • [Cites] Cell. 1996 Jan 26;84(2):321-30 [8565077.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3444-9 [8622955.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12359-63 [8901586.001]
  • [Cites] Cell. 1996 Nov 15;87(4):697-708 [8929538.001]
  • [Cites] Cell. 1997 May 30;89(5):773-9 [9182765.001]
  • [Cites] Nat Genet. 1997 Jul;16(3):307-10 [9207800.001]
  • [Cites] Blood. 1999 Mar 15;93(6):1817-24 [10068652.001]
  • [Cites] J Med Genet. 1999 Mar;36(3):177-82 [10204840.001]
  • [Cites] Nat Struct Biol. 1999 Jul;6(7):615-9 [10404214.001]
  • [Cites] Nat Genet. 1999 Oct;23(2):166-75 [10508512.001]
  • [Cites] Am J Hum Genet. 1999 Nov;65(5):1268-78 [10521292.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3565-72 [15297309.001]
  • [Cites] Cell. 2004 Dec 17;119(6):847-60 [15607980.001]
  • [Cites] J Mol Biol. 2005 Jun 10;349(3):608-20 [15878177.001]
  • [Cites] Blood. 2005 Jul 15;106(2):494-504 [15784726.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1364-72 [11830488.001]
  • (PMID = 17290219.001).
  • [ISSN] 0261-4189
  • [Journal-full-title] The EMBO journal
  • [ISO-abbreviation] EMBO J.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA23108; United States / NCI NIH HHS / CA / P30 CA023108; United States / NCI NIH HHS / CA / R01CA89419; United States / NIGMS NIH HHS / GM / T32 GM008704; United States / NCI NIH HHS / CA / R01 CA089419; United States / NIGMS NIH HHS / GM / T32GM08704
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cbfb protein, mouse; 0 / Core Binding Factor Alpha 1 Subunit; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Core Binding Factor beta Subunit; 0 / DNA Primers; 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC1852839
  •  go-up   go-down


29. Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S, Loren A, Phillips J, Nasta S, Perl A, Schuster S, Tsai D, Sohal A, Veloso E, Emerson S, June CH: A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood; 2006 Feb 15;107(4):1325-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Donor lymphocyte infusions (DLIs) induce potent graft versus tumor (GVT) effects for relapsed chronic myelogenous leukemia (CML) after allogeneic stem cell transplantation (SCT) but are disappointing for other diseases.
  • We performed a phase 1 trial of ex vivo-activated DLI (aDLI) for 18 patients with relapse after SCT.
  • Seven patients developed acute graft versus host disease (GVHD) (5 grade I-II, 2 grade III), and 4 developed chronic GVHD.
  • Eight patients achieved complete remission, including 4 of 7 with acute lymphocytic leukemia (ALL), 2 of 4 with acute myelogenous leukemia (AML), 1 with chronic lymphocytic leukemia (CLL), and 1 of 2 with non-Hodgkin lymphoma (NHL).
  • [MeSH-major] Antigens, CD28 / blood. Antigens, CD8 / blood. Leukemia / therapy. Lymphocyte Transfusion / adverse effects. Lymphoma / therapy. Stem Cell Transplantation / adverse effects

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16269610.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD28; 0 / Antigens, CD8
  •  go-up   go-down


30. Lee SH, Lee MH, Lee JH, Min YH, Lee KH, Cheong JW, Lee J, Park KW, Kang JH, Kim K, Kim WS, Jung CW, Choi SJ, Lee JH, Park K: Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission. Biol Blood Marrow Transplant; 2005 Feb;11(2):122-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission.
  • Allogeneic stem cell transplantation (ASCT) has improved the outcome of acute myelogenous leukemia (AML).
  • To further improve the treatment outcome of ASCT in AML, finding a modifiable prognostic factor is mandatory.
  • We evaluated the effect of CD34(+) cell dose on survival in allogeneic bone marrow transplantation (BMT) from HLA-matched sibling donors for AML patients in first complete remission (CR1).
  • The high CD34(+) cell dose patients had better overall survival (5-year overall survival rate, 75% +/- 6% vs 52% +/- 9%; P = .01) and leukemia-free survival (5-year leukemia-free survival rate, 70% +/- 6% vs 44% +/- 9%; P = .04).
  • CD34(+) cell dose was the only independent prognostic factor in overall survival and leukemia-free survival.
  • The high CD34(+) cell dose group had a lower relapse incidence with a borderline statistical significance (5-year relapse rate, 27% +/- 6% vs 50% +/- 10%; P = .09).
  • There were no differences in the engraftment of neutrophil and platelet, grade II-IV acute graft-versus-host disease (GVHD), extensive-stage chronic GVHD, and transplant-related mortality between the high and low CD34(+) cell dose groups.
  • We confirmed that high CD34(+) cell dose favorably affects the outcomes in allogeneic BMT for AML.
  • The effort to attain a high CD34(+) cell dose should be pursued during bone marrow harvest in allogeneic BMT for AML in CR1.
  • [MeSH-major] Antigens, CD34 / analysis. Bone Marrow Cells / cytology. Bone Marrow Transplantation. Leukemia, Myeloid, Acute. Tissue Donors


31. Hartwig M, Weigel S, Bernig T, Bader P, Dölken R, Beck J: Maintenance immunotherapy by repetitive low-dose donor lymphocytes infusions in a child with relapse state aml after allogeneic stem cell transplantation. Pediatr Hematol Oncol; 2007 Mar;24(2):137-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maintenance immunotherapy by repetitive low-dose donor lymphocytes infusions in a child with relapse state aml after allogeneic stem cell transplantation.
  • The treatment of a child with a relapsed state acute leukemia after allogeneic stem cell transplantation (allo-SCT) is a challenge.
  • The authors report about a child with an acute myelogenous leukemia (AML), which relapsed after allo-SCT despite immunological intervention.
  • Because of an immense risk for a further relapse, an immunological maintenance therapy was also performed, consisting of repetitive infusions of low doses of donor lymphocytes combined with low-dose chemotherapy.
  • [MeSH-major] Graft vs Host Disease / therapy. Leukemia, Myeloid, Acute / therapy. Lymphocyte Transfusion. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454780.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Kikushige Y, Takase K, Miyamoto T, Numata A, Kamesaki K, Fukuda T, Nagafuji K, Gondo H, Harada M: Late relapse of acute myelogenous leukemia followed by epstein-barr virus-associated lymphoproliferative disease 11 years after allogeneic bone marrow transplantation. Int J Hematol; 2006 Dec;84(5):441-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late relapse of acute myelogenous leukemia followed by epstein-barr virus-associated lymphoproliferative disease 11 years after allogeneic bone marrow transplantation.
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) following myeloablative conditioning represents the treatment of choice for patients with chemotherapy-resistant leukemia.
  • We describe a 49-year-old man with advanced, refractory acute myelogenous leukemia (AML) that was treated successfully by allogeneic bone marrow transplantation from a sibling donor with HLA mismatched at 1 locus.
  • AML relapse was documented 11 years after transplantation.
  • As a result, immune surveillance against remaining quiescent leukemic cells as well as viral infection may have been defective, leading to the relapse of leukemia and EBV-associated PTLD.
  • [MeSH-major] Bone Marrow Transplantation. Epstein-Barr Virus Infections. Herpesvirus 4, Human. Leukemia, Myeloid, Acute


33. Chen SH, Hung IJ, Yang CP, Jaing TH, Fang EC, Yang SH, Tseng CK: Allogeneic related bone marrow transplantation in children--a single center experience. Acta Paediatr Taiwan; 2005 Nov-Dec;46(6):352-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Allogeneic bone marrow grafts from 19 donors (18 human leukocyte antigen (HLA)-matched sibling donors and 1 one antigen-mismatched related donor) were transplanted into patients aged 3-17 years (16 with leukemia and 3 with non-malignant disease).
  • Acute graft versus host disease (GVHD) grade II to IV developed in 8 patients (42.
  • Six patients (31.6%) had relapse of their underlying malignant disease, and one of them is still alive.
  • Seven patients died (5 because of relapse and/or disease progression and 2 because of infectious complication).
  • The underlying diseases were acute lymphoblastic leukemia (ALL; 4 cases: 3 CR2, 1 Ph+), acute myeloid leukemia (AML; 2 cases: 1 CR2, 1 refractory), and juvenile chronic myelogenous leukemia (JCML; 1 case).
  • Relapsed leukemia at an extramedullary site occurred in 2 patients with ALL after BMT.
  • Although our data should be interpreted cautiously considering the limited number of patients, isolated extramedullary relapse seems to be common after allogeneic BMT.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Leukemia / therapy. Male. Recurrence. Retrospective Studies. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16640037.001).
  • [ISSN] 1608-8115
  • [Journal-full-title] Acta paediatrica Taiwanica = Taiwan er ke yi xue hui za zhi
  • [ISO-abbreviation] Acta Paediatr Taiwan
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


34. Kikushige Y, Takase K, Sata K, Aoki K, Numata A, Miyamoto T, Fukuda T, Gondo H, Harada M, Nagafuji K: Repeated relapses of acute myelogenous leukemia in the isolated extramedullary sites following allogeneic bone marrow transplantations. Intern Med; 2007;46(13):1011-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeated relapses of acute myelogenous leukemia in the isolated extramedullary sites following allogeneic bone marrow transplantations.
  • Isolated extramedullary (EM) relapses of acute myelogenous leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) have been reported to be rare, and are usually followed by bone marrow relapses.
  • We report a 49-year-old man with AML with the unfavorable chromosome abnormality 7q-, who was treated by allo-HSCT.
  • Fifteen months after allo-HSCT, the patient initially developed a relapse only in his inguinal lymph nodes, and then bone marrow relapse became evident one month after the EM relapse.
  • Subsequently, the patient received chemotherapy and a second allo-HSCT from another donor, but he suffered another relapse in different EM sites including the skin and central nervous system with a persistently normal marrow.
  • This case is characterized by repeated relapses in isolated EM sites after allo-HSCT and suggests that the anti-leukemic effects of chemotherapy and/or graft-versus-leukemia effects in the EM sites might not be so uniformly effective as that in the marrow.
  • Accordingly, we should be aware that AML relapses can occur repeatedly only in isolated EM sites post allo-HSCT, resulting in treatment failure and a poor prognosis.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / pathology. Leukemia, Myeloid, Acute / therapy. Leukemic Infiltration / pathology. Lymph Nodes / pathology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17603242.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


35. Gahrton G: Risk assessment in haematopoietic stem cell transplantation: impact of donor-recipient sex combination in allogeneic transplantation. Best Pract Res Clin Haematol; 2007 Jun;20(2):219-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In large retrospective registry studies of several thousands of patients with aplastic anemia, chronic myelocytic leukemia (CML), acute myelocytic leukemia (AML), and multiple myeloma, chronic graft-versus-host disease (cGVHD) was more frequent and transplant-related mortality (TRM) higher in males with a female donor (F-->M) than in other donor-recipient sex combinations.
  • Graft rejection was more frequent in females with a male donor (M-->F) in aplastic anemia, and a graft-versus-tumor effect (GVT) was documented as a reduced relapse rate in F-->M in CML, AML and multiple myeloma.
  • The overall survival was adversely affected in F-->M in aplastic anemia, AML and CML and in M-->F in aplastic anemia.
  • [MeSH-minor] Anemia, Aplastic / therapy. Female. Graft Rejection / immunology. Graft vs Host Disease / etiology. Graft vs Host Disease / immunology. Graft vs Tumor Effect / immunology. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology. Male. Recurrence. Risk Assessment. Sex Factors. Survival Analysis

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448958.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 37
  •  go-up   go-down


36. Russell JA, Irish W, Balogh A, Chaudhry MA, Savoie ML, Turner AR, Larratt L, Storek J, Bahlis NJ, Brown CB, Quinlan D, Geddes M, Zacarias N, Daly A, Duggan P, Stewart DA: The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. Biol Blood Marrow Transplant; 2010 Apr;16(4):509-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia.
  • A combination of fludarabine (Flu) and daily i.v. busulfan (Bu) is well tolerated and effective in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for acute myelogenous leukemia (AML).
  • The addition of rabbit antithymocyte globulin (ATG) may reduce morbidity and mortality from graft-versus-host disease (GVHD), but lead to increased relapse.
  • Although nonrelapse mortality (NRM) at 3 years did not differ between the groups, the inclusion of TBI significantly reduced relapse (hazard ratio [HR] = 0.29; 95% confidence interval [CI] = 0.15-0.54; P = .0001).
  • This study confirms the importance of regimen intensity in allogeneic HSCT for AML.
  • Bu, Flu, 400 cGy TBI, and ATG provides a well-tolerated regimen with antileukemic activity in AML comparable to that of other, conventional myeloablative (MA) regimens.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • (PMID = 19948235.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antilymphocyte Serum; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine
  •  go-up   go-down


37. Xu SX, Tang XH, Chen HQ, Feng B, Xu HQ, Chen XP, Tang XF: [Comparison of total body irradiation-cyclophosphamide versus busulphan-cyclophosphamide as conditioning regimens for myelogenous leukemia: a meta-analysis]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec;16(6):1354-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of total body irradiation-cyclophosphamide versus busulphan-cyclophosphamide as conditioning regimens for myelogenous leukemia: a meta-analysis].
  • Total body irradiation combined with cyclophosphamide (TBI/CY) and busulphan combined with cyclophosphamide (BU/CY) are standard conditioning regimens in hematological stem cell transplantation for patients with myelogenous leukemia.
  • This study was aimed to compare the therapeutic efficacy of TBI/CY and BU/CY as conditioning regiment for acute or chronic myelogenous leukemia.
  • Comparative studies were carried out on clinical therapeutic effects of TBI/CY and BU/CY including stem cell engraftment, relapse, complications, transplant-related mortality, and disease-free survival.
  • No significantly difference was found in engraftment failure and transplant-related mortality resulting from TBI/CY and BU/CY conditioning regimens, but the incidence of veno-occlusion of liver and hemorrhagic cystitis obviously increased in BU/CY group after transplantation, the acute GVHD, interstitial pneumonia and cataract significantly increased in TBI/CY group.
  • The relapse rate of AML in TBI/CY group was lower than that in BU/CY group, and the rate of long-term disease-free survival of AML patients in TBI/CY group also significantly lower than that in BU/CY group, but the relapse rate of CML in TBI/CY group after transplantation was obviously higher than that in BU/CY group, but there was no difference in longterm disease-free survival rate between the two conditioning regimens mentioned above.
  • It is concluded that the meta-analysis confirms different effects of TBI/CY and BU/CY regimens on myelogenous leukemia transplantation.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19099643.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Meta-Analysis
  • [Publication-country] China
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; G1LN9045DK / Busulfan
  •  go-up   go-down


38. Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, Min CK, Lee S, Cho SG, Jin JY, Lee JW, Kim CC: Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant; 2009 Jun;15(6):704-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
  • In this study, we investigated the effects of low-dose antithymocyte globulin (ATG, thymoglobulin) in the prevention of acute graft-versus-host disease (aGVHD) in mismatched, unrelated hematopoietic stem cell transplantations (uHSCTs) in patients with the single disease entity of acute myelogenous leukemia (AML).
  • Patients (n = 103) with a variable risk for AML who received uHSCTs from available Asian and Caucasian donors were enrolled.
  • These results suggest that in mismatched uHSCT, a low dose of ATG (total 2.5 mg/kg) may prevent moderate to severe aGVHD, with comparable rates of relapse and CMV reactivation and a greatly decreased rate of NRM.
  • [MeSH-major] Antilymphocyte Serum / therapeutic use. Graft vs Host Disease / prevention & control. Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia, Myeloid / surgery
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Chronic Disease. Disease-Free Survival. Female. HLA Antigens / analysis. Histocompatibility. Humans. Incidence. Living Donors. Male. Methotrexate / administration & dosage. Middle Aged. Prospective Studies. Survival Analysis. T-Lymphocytes / immunology. Tacrolimus / administration & dosage. Transplantation Conditioning. Transplantation, Homologous / adverse effects. Young Adult

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19450755.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antilymphocyte Serum; 0 / HLA Antigens; WM0HAQ4WNM / Tacrolimus; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


39. Karp JE, Smith BD, Levis MJ, Gore SD, Greer J, Hattenburg C, Briel J, Jones RJ, Wright JJ, Colevas AD: Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res; 2007 Aug 1;13(15 Pt 1):4467-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
  • In a phase I study of flavopiridol followed by 1-beta-d-arabinofuranosylcytosine (ara-C) and mitoxantrone, overall response rate for adults with relapsed and refractory acute myelogenous leukemias (AML) was 31%.
  • We have now completed a phase II study of sequential flavopiridol, ara-C, and mitoxantrone in 62 adults with poor-risk AML.
  • Complete remissions (CR) were achieved in 12 of 15 (75%) newly diagnosed secondary AML, 18 of 24 (75%) first relapse after short CR (median CR, 9 months, including prior allotransplant), and 2 of 13 (15%) primary refractory but 0 of 10 multiply refractory AML.
  • CONCLUSIONS: Flavopiridol has anti-AML activity directly and in combination with ara-C and mitoxantrone.
  • This timed sequential regimen induces durable CRs in a significant proportion of adults with newly diagnosed secondary AML (including complex cytogenetics) and adults with AML in first relapse after short first CR.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671131.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01-RR0052; United States / NCI NIH HHS / CA / U01 CA70095
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Piperidines; 04079A1RDZ / Cytarabine; 45AD6X575G / alvocidib; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


40. Ando T, Mitani N, Matsui K, Yamashita K, Nomiyama J, Tsuru M, Yujiri T, Tanizawa Y: Recurrent extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation in a patient with the chromosomal abnormality t(8;21) and CD56-positivity. Int J Hematol; 2009 Oct;90(3):374-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent extramedullary relapse of acute myelogenous leukemia after allogeneic hematopoietic stem cell transplantation in a patient with the chromosomal abnormality t(8;21) and CD56-positivity.
  • Isolated extramedullary (EM) relapse of acute myelogenous leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is rare.
  • We describe an AML patient showing the chromosomal abnormality t(8;21) and CD56 expression who experienced a unique EM relapse after allo-HSCT.
  • Approximately 10 months after allo-HSCT, he experienced relapse involving the femur and lumbar vertebrae and, subsequently, an EM relapse of the stomach.
  • Although we administered only local radiotherapy and not systemic chemotherapy, he showed no bone marrow relapse on long-term follow-up after achieving complete hematological remission.
  • These findings suggest that the graft-versus-leukemia effect may preferentially maintain marrow remission rather than prevent EM relapse.
  • In addition, our findings show that extended survival is possible after EM relapse following allo-HSCT in patients with marrow hematopoiesis of donor origin, and that augmentation of the graft-versus-leukemia effect may be useful.
  • [MeSH-major] Graft vs Leukemia Effect. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute. Stomach Neoplasms. Translocation, Genetic


41. Kornblau SM, Singh N, Qiu Y, Chen W, Zhang N, Coombes KR: Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia. Clin Cancer Res; 2010 Mar 15;16(6):1865-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia.
  • PURPOSE: The Forkhead transcription factors (FOXO) are tumor suppressor genes regulating differentiation, metabolism, and apoptosis that functionally interact with signal transduction pathways shown to be deregulated and prognostic in acute myelogenous leukemia (AML).
  • This study evaluated the level of expression and the prognostic relevance of total and phosphorylated FOXO3A protein in AML.
  • EXPERIMENTAL DESIGN: We used reverse-phase protein array methods to measure the level of total and phosphoprotein expression of FOXO3A, in leukemia-enriched protein samples from 511 newly diagnosed AML patients.
  • Levels of total FOXO3A were higher at relapse compared with diagnosis.
  • CONCLUSIONS: High levels of phosphorylation of FOXO3A is a therapeutically targetable, independent adverse prognostic factor in AML.
  • [MeSH-major] Forkhead Transcription Factors / metabolism. Leukemia, Myeloid, Acute / metabolism. Leukemia, Promyelocytic, Acute / metabolism. Neoplasm Proteins / metabolism

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Mol Med. 2008 May;14(5):219-27 [18403263.001]
  • [Cites] Breast Cancer Res. 2008;10(1):R21 [18312651.001]
  • [Cites] Eur J Haematol. 2008 Aug;81(2):83-93 [18363870.001]
  • [Cites] Mol Cell Biol. 2008 Oct;28(19):5886-98 [18644865.001]
  • [Cites] Blood. 2009 Jan 1;113(1):154-64 [18840713.001]
  • [Cites] Cell Cycle. 2008 Dec 15;7(24):3829-39 [19066462.001]
  • [Cites] Clin Cancer Res. 2009 Feb 1;15(3):752-7 [19188143.001]
  • [Cites] Bioinformatics. 2009 Jun 1;25(11):1384-9 [19336447.001]
  • [Cites] Leuk Res. 2009 Dec;33(12):1706-9 [19457552.001]
  • [Cites] Cancer Invest. 2009 Jan;27(1):52-9 [19160093.001]
  • [Cites] Genes Dev. 2000 Jan 15;14(2):142-6 [10702024.001]
  • [Cites] Mol Cell Biol. 2001 Feb;21(3):952-65 [11154281.001]
  • [Cites] Biochem J. 2001 May 1;355(Pt 3):597-607 [11311120.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5736-46 [11607823.001]
  • [Cites] Trends Biochem Sci. 2002 Jul;27(7):352-60 [12114024.001]
  • [Cites] Cancer Cell. 2002 Jul;2(1):81-91 [12150827.001]
  • [Cites] J Biol Chem. 2003 Feb 21;278(8):5871-82 [12488318.001]
  • [Cites] Cell. 2004 Apr 16;117(2):225-37 [15084260.001]
  • [Cites] Oncogene. 2004 Apr 22;23(19):3338-49 [14981546.001]
  • [Cites] Mol Cell. 2004 May 21;14(4):416-8 [15149589.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2869-72 [8187070.001]
  • [Cites] J Histochem Cytochem. 1996 Dec;44(12):1353-62 [8985127.001]
  • [Cites] Oncogene. 1997 Jan 16;14(2):195-202 [9010221.001]
  • [Cites] Genomics. 1998 Jan 15;47(2):187-99 [9479491.001]
  • [Cites] Cell. 1999 Mar 19;96(6):857-68 [10102273.001]
  • [Cites] BMC Neurosci. 2004 Nov 29;5:48 [15569384.001]
  • [Cites] Cell Cycle. 2005 Jul;4(7):908-13 [15917664.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7410-25 [16288288.001]
  • [Cites] Cell. 2006 Jun 2;125(5):987-1001 [16751106.001]
  • [Cites] Exp Gerontol. 2006 Aug;41(8):709-17 [16806782.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2358-65 [16763210.001]
  • [Cites] Science. 2006 Oct 13;314(5797):294-7 [17038621.001]
  • [Cites] Mol Cancer Ther. 2006 Oct;5(10):2512-21 [17041095.001]
  • [Cites] Cell. 2007 Jan 26;128(2):309-23 [17254969.001]
  • [Cites] Cell. 2007 Jan 26;128(2):325-39 [17254970.001]
  • [Cites] Cell Death Differ. 2007 Mar;14(3):534-47 [16888645.001]
  • [Cites] Bioinformatics. 2007 Aug 1;23(15):1986-94 [17599930.001]
  • [Cites] Nat Rev Cancer. 2007 Nov;7(11):847-59 [17943136.001]
  • [Cites] Cancer Sci. 2007 Dec;98(12):1949-58 [17900262.001]
  • [Cites] Oncogene. 2007 Nov 1;26(50):7081-91 [17496928.001]
  • [Cites] Nucleic Acids Res. 2007;35(20):6984-94 [17940099.001]
  • [Cites] Nat Cell Biol. 2008 Feb;10(2):138-48 [18204439.001]
  • [Cites] Cell Stem Cell. 2007 Jun 7;1(1):101-12 [18371339.001]
  • [Cites] Oncogene. 2008 Apr 7;27(16):2276-88 [18391970.001]
  • [Cites] Oncogene. 2008 Apr 7;27(16):2351-63 [18391977.001]
  • [Cites] Expert Opin Ther Targets. 2008 Jul;12(7):905-16 [18554157.001]
  • (PMID = 20215543.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA108631
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / FOXO3 protein, human; 0 / Forkhead Transcription Factors; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS378348; NLM/ PMC3385949
  •  go-up   go-down


42. Moore J, Nivison-Smith I, Goh K, Ma D, Bradstock K, Szer J, Durrant S, Schwarer A, Bardy P, Herrmann R, Dodds A: Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant; 2007 May;13(5):601-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.
  • Recent studies have shown comparable survival outcomes for unrelated donor (URD) stem cell transplantation in chronic myelogenous leukemia compared to sibling donors.
  • We compared outcomes for 105 patients aged 16 to 59 years undergoing URD transplants for acute myelogenous leukemia (AML) who were reported to the Australasian Bone Marrow Transplant Recipient Registry between 1992 and 2002, and a strictly selected matching set of 105 HLA-matched sibling donor (MSD) transplants.
  • There was no significant difference between URD and MSD controls in the distributions of time from diagnosis to transplant, donor-recipient sex match, prior therapies, donor age, or performance status.
  • There was no difference in the cumulative incidence of acute graft-versus-host disease grade II or above at 100 days.
  • Relapse occurred in 28% of good risk URD subjects and 16% of siblings (P = .3), and in poor risk subjects 39% and 29%, respectively (P = .2).
  • Based on this data, URD allografts should be considered in AML patients without a matched sibling donor.
  • This study provides a rationale for a larger prospective study of risk factors in allogeneic transplantation for AML and a guide on the subset of patients who may most benefit from an unrelated donor allograft in AML.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia, Myeloid, Acute / therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448920.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Spoo AC, Lübbert M, Wierda WG, Burger JA: CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood; 2007 Jan 15;109(2):786-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXCR4 is a prognostic marker in acute myelogenous leukemia.
  • CXCR4 chemokine receptors retain hematopoietic progenitors and leukemia cells within the marrow microenvironment.
  • We prospectively evaluated the prognostic implication of CXCR4 in 90 consecutive patients with acute myelogenous leukemia (AML) by flow cytometry.
  • We found that low CXCR4 expression on AML cells correlated with a better prognosis, resulting in a longer relapse-free and overall survival of 24.3+/-2.9 months for low CXCR4-expressing patients, compared with 17.4+/-3.4 months for intermediate and 12.8+/-2 months (mean+/-SEM) for patients with high expression.
  • We conclude that CXCR4 expression in AML is an independent prognostic predictor for disease relapse and survival that can rapidly and easily be determined at disease presentation.
  • These findings warrant further investigation into the role of CXCR4 in AML and suggest that CXCR4 should be incorporated into the risk assessment of AML patients.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / metabolism. Receptors, CXCR4 / metabolism


44. Ustün C, Kalla A, Bollag RJ, Manaloo E, Kulharya A, Jillella A: Relapsed acute myelogenous leukemia occurring after 18 years with recurrent novel chromosomal abnormality t(18;22)(q23;q11.2). Cancer Genet Cytogenet; 2007 Sep;177(2):135-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapsed acute myelogenous leukemia occurring after 18 years with recurrent novel chromosomal abnormality t(18;22)(q23;q11.2).
  • At age 4, she was diagnosed with acute myelogenous leukemia (AML) with t(18;22)(q23;q11.2) and received chemotherapy until age 6 under a pediatric study protocol.
  • The patient was treated for relapsed AML and at writing had been disease-free for 9 months.
  • Translocation between chromosomes 18 and 22 has been reported in indolent lymphoproliferative disorders, but not in AML.
  • Although we do not know the precise molecular etiology of this leukemia, the uncommon presentation for AML and late relapse with the same chromosomal abnormality may indicate a causal relationship between this novel chromosomal abnormality and the AML.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 18 / genetics. Chromosomes, Human, Pair 22 / genetics. Leukemia, Myeloid, Acute / genetics. Neoplasm Recurrence, Local / genetics

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17854669.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Bierings M, Nachman JB, Zwaan CM: Stem cell transplantation in pediatric leukemia and myelodysplasia: state of the art and current challenges. Curr Stem Cell Res Ther; 2007 Jan;2(1):53-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stem cell transplantation in pediatric leukemia and myelodysplasia: state of the art and current challenges.
  • The role of stem cell transplantation in the treatment of leukemia and myelodysplasia (MDS) in children has changed over the past decade.
  • In pediatric acute lymphoblastic leukemia (ALL), the overall cure-rate is high with conventional chemotherapy.
  • However, selected patients with a high-risk of relapse are often treated with allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first remission (CR1).
  • Patients with a bone-marrow relapse who attain a second remission frequently receive HSCT.
  • High minimal residual disease (MRD) levels directly prior to HSCT determines the relapse risk.
  • In pediatric acute myeloid leukemia (AML) the role of allo-HSCT in CR1 is declining, due to better outcome with modern multi-agent chemotherapy.
  • In relapsed AML patients, allo-HSCT still seems indispensable.
  • Targeted therapy may change the role of HSCT, in particular in chronic myeloid leukemia, where the role of allografting is changing in the imatinib era.
  • [MeSH-major] Leukemia / therapy. Myelodysplastic Syndromes / therapy. Stem Cell Transplantation / trends
  • [MeSH-minor] Child. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Myeloid, Acute / therapy


46. Huh HJ, Huh JW, Yoo ES, Seong CM, Lee M, Hong KS, Chung WS: hTERT mRNA levels by real-time RT-PCR in acute myelogenous leukemia. Am J Hematol; 2005 Aug;79(4):267-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] hTERT mRNA levels by real-time RT-PCR in acute myelogenous leukemia.
  • The purpose of this study was to investigate whether levels of hTERT mRNA, as determined by real-time RT-PCR, are associated with prognosis and clinical course in AML patients.
  • Fifty-four bone marrow specimens from 21 patients diagnosed with de-novo AML were included.
  • The expression rates of hTERT mRNA were significantly higher at diagnosis (73%) and during relapse (80%) than during remission (27%) (P<0.05).
  • The median RR for diagnosis or relapse was significantly higher than that for patients in remission (P<0.05).
  • Among seven patients with high hTERT mRNA levels (RR>9.51), 4 failed to achieve complete remission (CR), whereas 4 of 5 patients without hTERT mRNA expression at diagnosis or during relapse achieved CR (P>0.05).
  • Patients showing a trend of increasing hTERT mRNA levels failed to reach a second CR after relapse, while those with a trend toward decreasing hTERT mRNA did achieve CR.
  • Serial and quantitative analysis of hTERT mRNA may be a useful marker for prediction of prognosis and monitoring in AML patients.
  • [MeSH-major] Biomarkers, Tumor / analysis. DNA-Binding Proteins / analysis. Leukemia, Myeloid, Acute / diagnosis. RNA, Messenger / analysis. Telomerase / analysis

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16044449.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


47. Robin M, Porcher R, De Castro Araujo R, de Latour RP, Devergie A, Rocha V, Larghero J, Adès L, Ribaud P, Mary JY, Socié G: Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor. Biol Blood Marrow Transplant; 2007 Nov;13(11):1304-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients transplanted for aplastic anemia, chronic myelogenous leukemia (CML), and acute myelogenous leukemia (AML) were included.
  • Thirty patients died beyond the first year, causes of death were relapse (n = 10) and infections (n = 19, associated with graft-versus-host disease [GVHD] in 16 patients).
  • Extensive cGVHD was the only risk factor for non-HCV viral infections in patients transplanted for AML or CML (HR: 2.7, 95%CI: 1.4-5.1, P = .002).
  • [MeSH-minor] Adolescent. Adult. Anemia, Aplastic / therapy. Female. France / epidemiology. Graft vs Host Disease. Humans. Incidence. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Myeloid, Acute / therapy. Male. Retrospective Studies. Risk Factors. Transplantation, Homologous / adverse effects


48. Ando T, Mitani N, Matsunaga K, Nakazora T, Gondo T, Yujiri T, Tanizawa Y: Gemtuzumab ozogamicin therapy for isolated extramedullary AML relapse after allogeneic hematopoietic stem-cell transplantation. Tohoku J Exp Med; 2010 Feb;220(2):121-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemtuzumab ozogamicin therapy for isolated extramedullary AML relapse after allogeneic hematopoietic stem-cell transplantation.
  • The treatment of isolated extramedullary relapse (IEMR) after allogeneic hematopoietic stem-cell transplantation (allo-HSCT) poses a challenge for which no standard approach exists.
  • Gemtuzumab ozogamicin (GO) is a recombinant humanized monoclonal antibody, conjugated to calicheamicin, which targets the CD33 antigen that is expressed in acute myelogenous leukemia (AML) blasts.
  • The selectivity of GO for CD33-positive leukemic cells makes it an attractive agent for use in patients with multiple sites of IEMR after allo-HSCT, because GO does not suppress cells responsible for the putative graft-versus-leukemia (GVL) effect.
  • Herein, we describe a 54-year-old male patient who developed AML with multiple sites of extramedullary (EM) relapse after allo-HSCT, and who exhibited apparent donor-derived hematopoiesis in the bone marrow.
  • A biopsy specimen from a lumbar soft tissue mass confirmed EM relapse, and revealed that donor T lymphocytes were present in the relapse site and that leukemic cells expressed CD33.
  • GO can be an effective therapy for IEMR after allo-HSCT, especially when cytotoxic T lymphocytes react to leukemic cells at the site of EM relapse.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Sarcoma, Myeloid / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Bone and Bones / radionuclide imaging. CD8-Positive T-Lymphocytes / pathology. Graft vs Leukemia Effect / immunology. Humans. Leukocytes / metabolism. Leukocytes / pathology. Lumbosacral Region / pathology. Lumbosacral Region / radionuclide imaging. Male. Middle Aged. Peroxidase / metabolism. Recurrence. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20139663.001).
  • [ISSN] 1349-3329
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / gemtuzumab; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


49. Schlenk RF, Pasquini MC, Pérez WS, Zhang MJ, Krauter J, Antin JH, Bashey A, Bolwell BJ, Büchner T, Cahn JY, Cairo MS, Copelan EA, Cutler CS, Döhner H, Gale RP, Ilhan O, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Nimer SD, Sierra J, Tallman MS, Weisdorf DJ, Horowitz MM, Ganser A, CIBMTR Acute Leukemia Working Committee: HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. Biol Blood Marrow Transplant; 2008 Feb;14(2):187-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR.
  • We studied the role of HLA-matched sibling hematopoietic cell transplantation (HCT) in treating t(8;21) acute myelogenous leukemia (AML) in first remission.
  • Outcomes of 118 patients receiving HCT and reported to the Center for International Blood and Marrow Transplant Research were compared with 132 similar patients receiving chemotherapy selected from 8 German AML Intergroup multicenter trials.
  • Transplants were associated with higher treatment-related mortality (TRM; relative risk [RR] 6.76, 95% confidence interval [CI] 2.95-15.45, P < .001), lower relapse (RR 0.47, 95% CI 0.25-0.85, P = .01), and similar relapse-free survival (P = .2).
  • In both cohorts, white blood cell count (WBC) at diagnosis >25 x 10(9)/L was associated with a higher relapse risk (RR = 2.09, P = .03), lower relapse-free (RR = 1.9, P = .008), and OS (RR = 1.91, P = .01).
  • In this cohort of patients with t(8;21) AML, HCT did not improve OS, because reduction of relapse was offset by high TRM.
  • These results suggest that patients with t(8;21) AML without poor prognostic factors have higher rates of survival after chemotherapy as a post remission therapy compared to HCT.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3767-75 [10577848.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5074-87 [16051954.001]
  • [Cites] N Engl J Med. 2001 Jan 18;344(3):175-81 [11172139.001]
  • [Cites] Br J Haematol. 2001 Feb;112(2):300-7 [11167822.001]
  • [Cites] Leuk Lymphoma. 2000 Dec;40(1-2):67-77 [11426630.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1309-10 [11965278.001]
  • [Cites] Blood. 2002 May 15;99(10):3517-23 [11986202.001]
  • [Cites] Blood. 2002 Aug 1;100(3):761-7 [12130483.001]
  • [Cites] Br J Haematol. 2002 Aug;118(2):385-400 [12139722.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1525-31 [12176866.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2292-302 [12239137.001]
  • [Cites] Blood. 2003 Jul 15;102(2):462-9 [12649129.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1521-8 [12886238.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4496-504 [14673036.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Ann Hematol. 2004 Jun;83(6):336-44 [15034758.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3741-50 [15289486.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1081-6 [2754449.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1825-31 [1391946.001]
  • [Cites] N Engl J Med. 1995 Jan 26;332(4):217-23 [7808487.001]
  • [Cites] Leukemia. 1996 Aug;10(8):1288-95 [8709633.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5705-17 [16110030.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1791-9 [16254134.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3904-11 [16921041.001]
  • [Cites] Br J Haematol. 2006 Oct;135(2):165-73 [16939487.001]
  • [Cites] Leukemia. 1996 Nov;10(11):1687-91 [8892667.001]
  • [Cites] Eur J Haematol. 1997 Jul;59(1):47-52 [9260580.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2978-86 [9376578.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] N Engl J Med. 1998 Dec 3;339(23):1649-56 [9834301.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1104-9 [15650049.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • (PMID = 18215779.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518-10; United States / NCI NIH HHS / CA / U24 CA076518; United States / NCI NIH HHS / CA / U24 CA076518-09; United States / NCI NIH HHS / CA / U24-CA76518; United States / NCI NIH HHS / CA / U24 CA076518-08; United States / NCI NIH HHS / CA / CA076518-08
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS39951; NLM/ PMC2531160
  •  go-up   go-down


50. Aoki T, Miyamoto T, Yoshida S, Yamamoto A, Yamauchi T, Yoshimoto G, Mori Y, Kamezaki K, Iwasaki H, Takenaka K, Harada N, Nagafuji K, Teshima T, Akashi K: Additional acquisition of t(1;21)(p32;q22) in a patient relapsing with acute myelogenous leukemia with NUP98-HOXA9. Int J Hematol; 2008 Dec;88(5):571-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Additional acquisition of t(1;21)(p32;q22) in a patient relapsing with acute myelogenous leukemia with NUP98-HOXA9.
  • We report a 29-year-old Japanese male with acute myelogenous leukemia (AML)-M4 with a cryptic t(7;11)(p15;p15), in which a chimeric NUP98-HOXA9 fusion was detected by polymerase chain reaction analysis and a chromosomal analysis showed 46,XY.
  • This is the first reported case with AML who had a cryptic t(7;11)(p15;p15), and additionally acquired t(1;21)(p32;q22) at relapse.
  • [MeSH-major] Chromosomes, Human / genetics. Core Binding Factor Alpha 2 Subunit / genetics. Homeodomain Proteins / genetics. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / therapy. Nuclear Pore Complex Proteins / genetics. Oncogene Proteins, Fusion / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1992 Mar;6(3):232 [1564964.001]
  • [Cites] Int J Hematol. 2006 Aug;84(2):136-42 [16926135.001]
  • [Cites] Blood. 1998 Jul 15;92(2):574-88 [9657758.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Sep;129(2):155-60 [11566347.001]
  • [Cites] Bone Marrow Transplant. 1997 Nov;20(10):821-6 [9404921.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11781-91 [17178874.001]
  • [Cites] Nat Genet. 1996 Feb;12(2):159-67 [8563754.001]
  • [Cites] Blood. 2005 Jan 15;105(2):784-93 [15454493.001]
  • [Cites] Cancer Invest. 2003;21(1):105-36 [12643014.001]
  • [Cites] Curr Opin Hematol. 2005 May;12(3):210-6 [15867577.001]
  • [Cites] Br J Haematol. 1997 Mar;96(4):682-7 [9074407.001]
  • [Cites] Oncogene. 2008 Jun 19;27(27):3765-79 [18264136.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1532-42 [12176867.001]
  • [Cites] Ann N Y Acad Sci. 2007 Jun;1106:114-42 [17442773.001]
  • [Cites] Blood. 2002 Jan 1;99(1):310-8 [11756186.001]
  • [Cites] Am J Hematol. 1994 Sep;47(1):62-4 [8042621.001]
  • [Cites] Haematologica. 2007 Jun;92(6):861-2 [17550866.001]
  • [Cites] Br J Haematol. 1999 Dec;107(3):600-4 [10583265.001]
  • [Cites] EMBO J. 2001 Feb 1;20(3):350-61 [11157742.001]
  • [Cites] Leukemia. 2001 Nov;15(11):1689-95 [11681408.001]
  • [Cites] Haematologica. 1997 May-Jun;82(3):364-70 [9234595.001]
  • (PMID = 19005624.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / AML1-ETO fusion protein, human; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Homeodomain Proteins; 0 / NUP98-HOXA9 fusion protein, human; 0 / Nuclear Pore Complex Proteins; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


51. Latagliata R, Breccia M, Fazi P, Iacobelli S, Martinelli G, Di Raimondo F, Sborgia M, Fabbiano F, Pirrotta MT, Zaccaria A, Amadori S, Caramatti C, Falzetti F, Candoni A, Mattei D, Morselli M, Alimena G, Vignetti M, Baccarani M, Mandelli F: Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. Br J Haematol; 2008 Dec;143(5):681-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia.
  • This randomized phase III clinical trial explored the efficacy of DaunoXome (DNX) versus Daunorubicin (DNR) in acute myeloid leukaemia (AML) patients aged >60 years.
  • Three hundred and one AML patients were randomized to receive DNR (45 mg/m(2) days 1-3) or DNX (80 mg/m(2) days 1-3) plus cytarabine (AraC; 100 mg/m(2) days 1-7).
  • After CR, DNX showed a higher incidence of early deaths (12.5% vs. 2.6% at 6 months, P = 0.053) but a lower incidence of relapse beyond 6 months (59% vs. 78% at 24 months, P = 0.064), with a cross in overall survival (OS) and disease-free survival (DFS) curves and a later advantage for DNX arm after 12 months from diagnosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Daunorubicin / administration & dosage. Leukemia, Myeloid, Acute / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18950458.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Liposomes; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


52. Callera F, Mulin CC, Rosa ES, Melo DB, Melo CM: High prevalence of morphological subtype FAB M1 in adults with de novo acute myeloid leukemia in São José dos Campos, São Paulo. Sao Paulo Med J; 2006 Jan 5;124(1):45-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High prevalence of morphological subtype FAB M1 in adults with de novo acute myeloid leukemia in São José dos Campos, São Paulo.
  • CONTEXT AND OBJECTIVE: Geographical variations have been described in acute myelogenous leukemia (AML).
  • The aim of this study was to demonstrate the high prevalence of French-American-British (FAB) M1 subtype in adults with de novo AML in São José dos Campos, State of São Paulo, Brazil.
  • METHODS: Records from 39 consecutive adult patients with de novo AML referred to Hospital Pio XII between January 2002 and September 2004 were reviewed.
  • The rates of remission, relapse, mortality according treatment phase, survival and leukemia-free survival were calculated.
  • The remission and the relapse rates were 82% and 41% respectively.
  • The mortality rate was 69% (induction of remission: 7/39, 17.9%; post induction: 10/32, 31.2%; and relapse: 10/16, 62.5%).
  • The survival rate was 30% and leukemia-free survival was 33%.
  • CONCLUSIONS: The study demonstrated a high prevalence of FAB M1 subtype in adults with de novo AML in São José dos Campos.
  • Our data suggest the occurrence of different regional prevalences of FAB AML categories in Brazil.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16612463.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  •  go-up   go-down


53. Alyea EP, Kim HT, Ho V, Cutler C, DeAngelo DJ, Stone R, Ritz J, Antin JH, Soiffer RJ: Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant; 2006 Oct;12(10):1047-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.
  • We reviewed 136 patients with advanced acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic transplantation to assess the impact of conditioning regimen intensity on outcome.
  • The cumulative risk of relapse was higher for patients after NST (61% vs 38%; P = .02).
  • Despite the high-risk features of patients with advanced AML or MDS undergoing NST, OS and PFS in these patients was similar to those in patients receiving myeloablative transplantation.
  • These results suggest that NST is a reasonable alternative for patients with advanced AML and MDS at high risk for complications after myeloablative transplantation.
  • [MeSH-major] Bone Marrow Transplantation. Busulfan / administration & dosage. Cyclophosphamide / administration & dosage. Leukemia, Myeloid / surgery. Myelodysplastic Syndromes / surgery. Peripheral Blood Stem Cell Transplantation. Transplantation Conditioning. Vidarabine / analogs & derivatives. Whole-Body Irradiation
  • [MeSH-minor] Acute Disease. Adult. Aged. Female. Graft Survival. Graft vs Host Disease / epidemiology. Graft vs Host Disease / etiology. Humans. Incidence. Kaplan-Meier Estimate. Male. Middle Aged. Recurrence. Reoperation. Retrospective Studies. Tissue Donors. Transplantation, Homologous / mortality. Treatment Outcome


54. Guzman ML, Li X, Corbett CA, Rossi RM, Bushnell T, Liesveld JL, Hébert J, Young F, Jordan CT: Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood; 2007 Dec 15;110(13):4436-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8).
  • Leukemia is thought to arise from malignant stem cells, which have been described for acute and chronic myeloid leukemia (AML and CML) and for acute lymphoblastic leukemia (ALL).
  • Leukemia stem cells (LSCs) are relatively resistant to current chemotherapy and likely contribute to disease relapse and progression.
  • Analysis of primary AML, blast crisis CML (bcCML), ALL, and chronic lymphoblastic leukemia (CLL) specimens showed rapid induction of cell death upon treatment with TDZD-8.
  • We conclude that TDZD-8 uses a unique and previously unknown mechanism to rapidly target leukemia cells, including malignant stem and progenitor populations.

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Aug 10;19(34):3941-7 [10951587.001]
  • [Cites] Int J Hematol. 2005 Aug;82(2):100-7 [16146839.001]
  • [Cites] Hematol Oncol. 2001 Sep;19(3):89-106 [11574931.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2301-7 [11588023.001]
  • [Cites] Blood. 2002 Jan 1;99(1):319-25 [11756187.001]
  • [Cites] J Med Chem. 2002 Mar 14;45(6):1292-9 [11881998.001]
  • [Cites] Leukemia. 2002 Apr;16(4):559-62 [11960332.001]
  • [Cites] Cell. 2002 Apr;109 Suppl:S81-96 [11983155.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1532-42 [12176867.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4594-601 [12393637.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16220-5 [12451177.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3142-9 [12468427.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1715-27 [12685823.001]
  • [Cites] Leukemia. 2004 Mar;18(3):505-12 [14737078.001]
  • [Cites] Cancer Lett. 2004 May 28;208(2):143-53 [15142672.001]
  • [Cites] Oncogene. 2004 Sep 20;23(43):7178-87 [15378078.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2919-25 [15242869.001]
  • [Cites] Am J Med. 1977 Jul;63(1):125-30 [267431.001]
  • [Cites] Baillieres Clin Haematol. 1991 Jul;4(3):577-98 [1958881.001]
  • [Cites] Cell Growth Differ. 1991 Nov;2(11):541-8 [1814434.001]
  • [Cites] J Exp Med. 1992 Jun 1;175(6):1501-9 [1375263.001]
  • [Cites] Leuk Lymphoma. 1992 Oct;8(3):201-11 [1337006.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Blood. 1996 Jun 1;87(11):4754-61 [8639846.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] J Biol Chem. 1997 Oct 31;272(44):27521-4 [9346882.001]
  • [Cites] Leukemia. 1997 Nov;11(11):1850-7 [9369417.001]
  • [Cites] Curr Opin Oncol. 1998 Jan;10(1):31-5 [9466482.001]
  • [Cites] Ann Hematol. 1998 Mar-Apr;76(3-4):145-51 [9619732.001]
  • [Cites] Blood. 1999 Sep 15;94(6):2056-64 [10477735.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2436-44 [15788695.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):297-309 [15803156.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4163-9 [15687234.001]
  • [Cites] Brain Res Mol Brain Res. 2005 Jun 13;137(1-2):193-201 [15950778.001]
  • [Cites] Ann N Y Acad Sci. 2005 Jun;1044:1-5 [15958691.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6520-7 [16166428.001]
  • [Cites] J Med Chem. 2005 Nov 17;48(23):7103-12 [16279768.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4261-8 [16150937.001]
  • [Cites] Br J Pharmacol. 2006 Mar;147(5):575-82 [16314851.001]
  • [Cites] Cancer Lett. 2006 Apr 8;235(1):1-10 [15907369.001]
  • [Cites] Crit Care Med. 2006 May;34(5):1489-96 [16557150.001]
  • [Cites] Shock. 2006 May;25(5):485-91 [16680013.001]
  • [Cites] Clin Immunol. 2006 Jul;120(1):57-67 [16631408.001]
  • [Cites] Leukemia. 2006 Jul;20(7):1316-9 [16642043.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Jul;318(1):79-89 [16601144.001]
  • [Cites] Nat Rev Cancer. 2006 Oct;6(10):813-23 [16990858.001]
  • [Cites] Shock. 2007 Jan;27(1):97-107 [17172987.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):281-94 [17384583.001]
  • [Cites] Leukemia. 2007 May;21(5):926-35 [17330101.001]
  • [Cites] Blood. 1996 Feb 1;87(3):1089-96 [8562934.001]
  • [Cites] Blood. 2005 Jul 15;106(2):673-80 [15797998.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Oct;37(10):2226-38 [16051512.001]
  • [Cites] Crit Care Med. 2005 Sep;33(9):1903-12 [16148458.001]
  • [Cites] Leukemia. 2000 Oct;14(10):1777-84 [11021753.001]
  • (PMID = 17785584.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA090446; United States / NCI NIH HHS / CA / R01 CA90446
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione; 0 / Sulfhydryl Compounds; 0 / Thiadiazoles; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; EC 2.7.11.13 / Protein Kinase C
  • [Other-IDs] NLM/ PMC2234782
  •  go-up   go-down


55. Gutierrez-Aguirre CH, Cantú-Rodríguez OG, Gonzalez-Llano O, Salazar-Riojas R, Martinez-González O, Jaime-Pérez JC, Morales-Toquero A, Tarín-Arzaga LC, Ruiz-Argüelles GJ, Gómez-Almaguer D: Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience. Hematology; 2007 Jun;12(3):193-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-myeloablative hematopoietic stem cell transplantation is of limited value in advanced or refractory acute myeloblastic leukemia. The Mexican experience.
  • Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective strategy for preventing relapse of acute myelogenous leukemia (AML).
  • We analyzed the outcome of 31 primary AML patients who received a reduced-intensity conditioning regimen for allogeneic HSCT in first or second remission.
  • Thirty-one AML patients, 20 in first complete remission (FCR), 8 in second complete remission (SCR) and 3 in a partial remission (SPR) were included.
  • Relapse for 20 patients in FCR was 35% compared to 91% for 11 in SCR/SPR (p < 0.05).
  • Conclusions. Reduced-intensity conditioning followed by allogeneic HSCT can induce stable remission in primary AML patients transplanted in FCR.
  • A high relapse rate was documented in patients with refractory or relapsed AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17558694.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 83HN0GTJ6D / Cyclosporine; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine
  •  go-up   go-down


56. Yamauchi T, Mori Y, Miyamoto T, Kamezaki K, Aoki T, Yamamoto A, Takenaka K, Iwasaki H, Harada N, Nagafuji K, Teshima T, Akashi K: Second unrelated cord blood transplantation using a reduced-intensity conditioning regimen combined with gemtuzumab ozogamicin in patients with relapsed acute myelogenous leukemia. Int J Hematol; 2009 Oct;90(3):416-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second unrelated cord blood transplantation using a reduced-intensity conditioning regimen combined with gemtuzumab ozogamicin in patients with relapsed acute myelogenous leukemia.
  • Gemtuzumab ozogamicin (GO) is an effective molecular-targeted agent for CD33-positive acute myelogenous leukemia (AML) patients who are resistant to conventional chemotherapy.
  • We report here for the first time three AML cases that relapsed after allogeneic SCT and underwent unrelated cord blood transplantation (UCBT) following reduced-intensity conditioning (RIC) comprising fludarabine, melphalan, and low-dose total body irradiation combined with GO.
  • Non-relapse mortality at day 100 was not documented.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Cord Blood Stem Cell Transplantation. Leukemia, Myeloid, Acute / drug therapy. Transplantation Conditioning / methods


57. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, Marsh SG, Geraghty D, Spellman S, Haagenson MD, Ladner M, Trachtenberg E, Parham P, Miller JS: Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood; 2010 Oct 7;116(14):2411-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia.
  • We KIR genotyped donors from 1409 unrelated transplants for acute myelogenous leukemia (AML; n = 1086) and acute lymphoblastic leukemia (ALL; n = 323).
  • Donor KIR genotype influenced transplantation outcome for AML but not ALL.
  • Compared with A haplotype motifs, centromeric and telomeric B motifs both contributed to relapse protection and improved survival, but Cen-B homozygosity had the strongest independent effect.
  • With Cen-B/B homozygous donors the cumulative incidence of relapse was 15.4% compared with 36.5% for Cen-A/A donors (relative risk of relapse 0.34; 95% confidence interval 0.2-0.57; P < .001).
  • Overall, significantly reduced relapse was achieved with donors having 2 or more B gene-content motifs (relative risk 0.64; 95% confidence interval 0.48-0.86; P = .003) for both HLA-matched and mismatched transplants.
  • Adopting this practice could result in superior disease-free survival for patients with AML.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Aug 1;102(3):814-9 [12689936.001]
  • [Cites] Br J Haematol. 2003 Oct;123(2):323-6 [14531915.001]
  • [Cites] Crit Rev Immunol. 2002;22(5-6):463-82 [12803322.001]
  • [Cites] J Immunol. 2004 Jan 1;172(1):644-50 [14688377.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1521-6 [14504099.001]
  • [Cites] Tissue Antigens. 2004 Mar;63(3):204-11 [14989709.001]
  • [Cites] Gene. 2004 Jun 23;335:121-31 [15194195.001]
  • [Cites] Science. 2004 Aug 6;305(5685):872-4 [15297676.001]
  • [Cites] N Engl J Med. 1989 Jun 29;320(26):1731-5 [2543925.001]
  • [Cites] Immunol Today. 1990 Jul;11(7):237-44 [2201309.001]
  • [Cites] Blood. 1993 Oct 15;82(8):2577-84 [8400305.001]
  • [Cites] Science. 1995 Apr 21;268(5209):405-8 [7716543.001]
  • [Cites] Immunity. 1995 May;2(5):439-49 [7749980.001]
  • [Cites] Immunity. 1997 Dec;7(6):739-51 [9430220.001]
  • [Cites] Immunity. 1997 Dec;7(6):753-63 [9430221.001]
  • [Cites] J Immunol. 1998 Jul 15;161(2):571-7 [9670929.001]
  • [Cites] Nat Rev Immunol. 2005 Mar;5(3):201-14 [15719024.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4878-84 [15731175.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 13;102(37):13224-9 [16141329.001]
  • [Cites] Immunogenetics. 2006 Aug;58(8):614-27 [16823588.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Aug;12(8):828-36 [16864053.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Aug;12(8):876-84 [16864058.001]
  • [Cites] Bone Marrow Transplant. 2006 Sep;38(6):437-44 [16892071.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3603-6 [17179231.001]
  • [Cites] Hum Immunol. 2007 May;68(5):309-23 [17462498.001]
  • [Cites] Immunogenetics. 2007 Jul;59(7):525-37 [17464504.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4246-54 [17724349.001]
  • [Cites] Stat Med. 2007 Oct 30;26(24):4505-19 [17348080.001]
  • [Cites] Tissue Antigens. 2007 Dec;70(6):449-54 [17900289.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4576-83 [17785583.001]
  • [Cites] J Immunol. 2008 Mar 15;180(6):3969-79 [18322206.001]
  • [Cites] Blood. 2008 Aug 1;112(3):461-9 [18650461.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2369-80 [18583565.001]
  • [Cites] Blood. 2009 Jan 15;113(3):726-32 [18945962.001]
  • [Cites] Blood. 2009 Mar 26;113(13):3110-8 [19059878.001]
  • [Cites] Trends Immunol. 2009 Apr;30(4):143-9 [19282243.001]
  • [Cites] JAMA. 2009 Jun 10;301(22):2349-61 [19509382.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 Apr;16(4):533-42 [19961944.001]
  • [Cites] Blood. 2010 Apr 15;115(15):3162-5 [20124216.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 Sep;16(9):1257-64 [20302958.001]
  • [Cites] J Immunol. 2002 Jan 1;168(1):240-52 [11751968.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4778-83 [10781084.001]
  • [Cites] Blood. 2001 Oct 1;98(7):2043-51 [11567988.001]
  • [Cites] N Engl J Med. 2001 Dec 20;345(25):1794-800 [11752355.001]
  • [Cites] Annu Rev Immunol. 2002;20:323-70 [11861606.001]
  • [Cites] Science. 2002 Mar 15;295(5562):2097-100 [11896281.001]
  • [Cites] J Immunol. 2002 Jul 1;169(1):239-47 [12077250.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3825-7 [12393440.001]
  • [CommentIn] Blood. 2010 Oct 7;116(14):2407-9 [20930082.001]
  • [CommentIn] Nat Rev Clin Oncol. 2011 Jan;8(1):3 [21218525.001]
  • (PMID = 20581313.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / 5U01HL069294; United States / NCI NIH HHS / CA / P01 CA065493; United States / NCI NIH HHS / CA / U24 CA076518; United States / PHS HHS / / HHSH234200637015C; United States / NCI NIH HHS / CA / U24-CA76518; United States / NHLBI NIH HHS / HL / U01 HL069294; United States / PHS HHS / / P01 111412
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, KIR
  • [Other-IDs] NLM/ PMC2953880
  •  go-up   go-down


58. Yasukawa K, Kato N, Aikawa K, Kodama K, Hamasaka A, Hata H: Neutrophilic eccrine hidradenitis with sclerodermoid change heralding the relapse of acute myelogenous leukemia: is this a paraneoplastic phenomenon? Dermatology; 2007;215(3):261-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neutrophilic eccrine hidradenitis with sclerodermoid change heralding the relapse of acute myelogenous leukemia: is this a paraneoplastic phenomenon?
  • [MeSH-major] Hidradenitis / etiology. Leukemia, Myeloid / complications. Paraneoplastic Syndromes / etiology
  • [MeSH-minor] Acute Disease. Antineoplastic Agents / therapeutic use. Humans. Male. Middle Aged. Recurrence

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17823528.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


59. Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQueen KL, Guethlein LA, Trachtenberg EA, Haagenson M, Horowitz MM, Klein JP, Weisdorf DJ: Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood; 2007 Jun 1;109(11):5058-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT.
  • We analyzed data from 2062 patients undergoing unrelated donor HCT for acute myeloid leukemia (AML; n = 556), chronic myeloid leukemia (CML; n = 1224), and myelodysplastic syndrome (MDS; n = 282).
  • Missing 1 or more KIR ligands versus the presence of all ligands protected against relapse in patients with early myeloid leukemia (relative risk [RR] = 0.54; n = 536, 95% confidence interval [CI] 0.30-0.95, P = .03).
  • In the subset of CML patients that received a transplant beyond 1 year from diagnosis (n = 479), missing a KIR ligand independently predicted a greater risk of developing grade 3-4 acute graft-versus-host disease (GVHD; RR = 1.58, 95% CI 1.13-2.22; P = .008).
  • These data support a genetically determined role for NK cells following unrelated HCT in myeloid leukemia.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2002 Mar 15;295(5562):2097-100 [11896281.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Aug;12(8):876-84 [16864058.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3825-7 [12393440.001]
  • [Cites] Nat Rev Immunol. 2003 Feb;3(2):108-22 [12563295.001]
  • [Cites] Blood. 2003 May 1;101(9):3730-40 [12511415.001]
  • [Cites] Blood. 2003 Aug 1;102(3):814-9 [12689936.001]
  • [Cites] J Immunol. 2004 Jan 1;172(1):644-50 [14688377.001]
  • [Cites] Adv Cancer Res. 2003;90:127-56 [14710949.001]
  • [Cites] Science. 1995 Apr 21;268(5209):405-8 [7716543.001]
  • [Cites] Immunity. 1997 Dec;7(6):739-51 [9430220.001]
  • [Cites] Blood. 1999 Jul 1;94(1):333-9 [10381530.001]
  • [Cites] Science. 1999 Jul 16;285(5426):412-5 [10411505.001]
  • [Cites] Mol Immunol. 2005 Feb;42(4):531-4 [15607809.001]
  • [Cites] Nat Rev Immunol. 2005 Mar;5(3):201-14 [15719024.001]
  • [Cites] Blood. 2005 May 15;105(10):4135-42 [15687235.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4878-84 [15731175.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4370-6 [16131567.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1935-47 [12200350.001]
  • (PMID = 17317850.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA111412; United States / NCI NIH HHS / CA / P01 CA 111412
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ligands; 0 / Receptors, Immunologic; 0 / Receptors, KIR
  • [Other-IDs] NLM/ PMC1885526
  •  go-up   go-down


60. Brown JR, Yeckes H, Friedberg JW, Neuberg D, Kim H, Nadler LM, Freedman AS: Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol; 2005 Apr 1;23(10):2208-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Current information on relapse of disease and second malignancies was obtained via an institutional review board-approved questionnaire sent to the referring oncologists.
  • RESULTS: Forty-two solid tumors, six non-MDS hematologic malignancies, 39 nonmelanoma skin cancers, and 68 cases of MDS/acute myelogenous leukemia (AML) were observed at a median follow-up of 9.5 years.
  • Although the incidence of MDS/AML starts to plateau, the incidence of solid tumors continues to rise.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Nov 1;23(31):8120-1; author reply 8121-2 [16258113.001]
  • (PMID = 15753460.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


61. Huang TS, Myklebust LM, Kjarland E, Gjertsen BT, Pendino F, Bruserud Ø, Døskeland SO, Lillehaug JR: LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro. Mol Cancer; 2007;6:31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro.
  • BACKGROUND: Relapse due to chemoresistant residual disease is a major cause of death in acute myelogenous leukemia (AML).
  • The present study was undertaken to elucidate the molecular mechanisms of chemoresistance by comparing differential gene expression in blasts from patients with resistant relapsing AML and chemosensitive AML.
  • RESULTS: About 20 genes were identified as preferentially expressed in blasts pooled from patients with resistant disease, as compared to chemosensitive AML blasts, based on differential gene expression screening.
  • Analysis of blasts from single patients disclosed that LEDGF/p75 was the most consistently upregulated mRNA in resistant AML.
  • Transfection experiments demonstrated that LEDGF/p75 and p52b antagonized daunorubicin-induced and cAMP-induced apoptosis in an AML cell line.
  • CONCLUSION: Our results provide evidence for an association between the overexpression of genes encoding survival proteins like LEDGF/p75 and chemo-resistance in acute myelogenous leukemia.
  • LEDGF/p75 has previously not been shown to protect against chemotherapy, and is a potential drug target in AML.
  • [MeSH-major] Apoptosis. Drug Resistance, Neoplasm / genetics. Gene Expression Regulation, Neoplastic. Intercellular Signaling Peptides and Proteins / metabolism. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / pathology. Lymphocyte Activation / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2000 Jan 7;267(1):373-81 [10623627.001]
  • [Cites] J Biol Chem. 1993 Apr 15;268(11):8332-40 [8385140.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4161-6 [10945624.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6227-9 [11103774.001]
  • [Cites] Eur J Biochem. 2001 Apr;268(7):2107-12 [11277934.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1752-9 [11535508.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Nov;299(2):434-41 [11602652.001]
  • [Cites] Blood. 2002 Feb 1;99(3):1097-8 [11822362.001]
  • [Cites] J Biol Chem. 2002 Jun 7;277(23):20783-93 [11909854.001]
  • [Cites] Oncogene. 2002 Aug 1;21(33):5056-68 [12140756.001]
  • [Cites] Cell Death Differ. 2002 Sep;9(9):915-25 [12181742.001]
  • [Cites] Autoimmun Rev. 2003 Sep;2(5):290-7 [12965181.001]
  • [Cites] Haematologica. 2004 Apr;89(4):391-402 [15075072.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]
  • [Cites] Hum Gene Ther. 1994 Jan;5(1):19-28 [8155767.001]
  • [Cites] N Engl J Med. 1994 Oct 6;331(14):896-903 [8078551.001]
  • [Cites] J Cell Sci. 1994 Dec;107 ( Pt 12):3363-77 [7706392.001]
  • [Cites] Blood. 1996 Mar 1;87(5):1710-7 [8634416.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] EMBO J. 1998 Nov 16;17(22):6723-9 [9822615.001]
  • [Cites] Mol Cell. 1998 Dec;2(6):751-9 [9885563.001]
  • [Cites] N Engl J Med. 1999 Sep 30;341(14):1051-62 [10502596.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1231-9 [10506708.001]
  • [Cites] Br J Haematol. 1999 Oct;107(1):69-79 [10520026.001]
  • [Cites] Leuk Res. 2005 Apr;29(4):467-70 [15725483.001]
  • [Cites] Cytometry B Clin Cytom. 2005 Mar;64(1):18-27 [15668952.001]
  • [Cites] J Cell Sci. 2005 Apr 15;118(Pt 8):1733-43 [15797927.001]
  • [Cites] Int J Oncol. 2006 May;28(5):1065-80 [16596222.001]
  • [Cites] Int J Oncol. 2006 Jul;29(1):57-64 [16773185.001]
  • [Cites] Haematologica. 2007 Mar;92(3):332-41 [17339182.001]
  • [Cites] Cell. 2004 Jul 23;118(2):217-28 [15260991.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2646-54 [15251987.001]
  • [Cites] Br J Haematol. 1989 May;72(1):45-53 [2736242.001]
  • [Cites] J Cell Physiol. 1991 Jan;146(1):73-80 [1846637.001]
  • [Cites] Acta Oncol. 1992;31(1):53-8 [1586506.001]
  • [Cites] Gene. 2000 Jan 25;242(1-2):265-73 [10721720.001]
  • (PMID = 17451600.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / lens epithelium-derived growth factor; E0399OZS9N / Cyclic AMP; ZS7284E0ZP / Daunorubicin
  • [Other-IDs] NLM/ PMC1876472
  •  go-up   go-down


62. Rahman MM, Madlambayan GJ, Cogle CR, McFadden G: Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus. Cytokine Growth Factor Rev; 2010 Apr-Jun;21(2-3):169-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, a major challenge with ABMT for patients with hematologic malignancies is disease relapse, mainly due to either contamination with cancerous hematopoietic stem and progenitor cells (HSPCs) within the autograft or the persistence of residual therapy-resistant disease niches within the patient.
  • Oncolytic viruses represent a promising therapeutic approach to prevent cancer relapse by eliminating tumor-initiating cells that contaminate the autograft.
  • MYXV, a novel oncolytic poxvirus with potent anti-cancer properties in a variety of in vivo tumor models, can specifically eliminate cancerous stem and progenitor cells from samples obtained from acute myelogenous leukemia (AML) patients, while sparing normal CD34+ hematopoietic stem and progenitor cells capable of rescuing hematopoiesis following high dose conditioning.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Curr Cancer Drug Targets. 2008 Feb;8(1):27-36 [18288941.001]
  • [Cites] Clin Infect Dis. 2008 May 15;46(10):1555-61 [18419490.001]
  • [Cites] Biochim Biophys Acta. 2008 Apr;1785(2):217-31 [18328829.001]
  • [Cites] Science. 2008 Apr 25;320(5875):531-5 [18436786.001]
  • [Cites] PLoS Pathog. 2008 Jul;4(7):e1000099 [18617992.001]
  • [Cites] Nat Rev Cancer. 2009 Jan;9(1):64-71 [19104515.001]
  • [Cites] J Virol. 2009 Jan;83(2):498-511 [18971273.001]
  • [Cites] J Virol. 2009 Jul;83(13):6883-99 [19386722.001]
  • [Cites] Cancer Immunol Immunother. 2009 Sep;58(9):1355-62 [19266198.001]
  • [Cites] Cytokine. 2009 Sep;47(3):199-205 [19640730.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4326-35 [12036858.001]
  • [Cites] Blood. 2002 Jul 1;100(1):59-66 [12070009.001]
  • [Cites] Viral Immunol. 2002;15(2):229-46 [12081009.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1957-64 [12200352.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):4968-76 [12208748.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):5001-7 [12208753.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):5013-8 [12208755.001]
  • [Cites] Virus Res. 2002 Sep;88(1-2):17-33 [12297325.001]
  • [Cites] Blood. 2003 Jul 1;102(1):377-87 [12637331.001]
  • [Cites] Leuk Lymphoma. 2003 Nov;44(11):1871-9 [14738138.001]
  • [Cites] Hum Gene Ther. 2004 Sep;15(9):821-31 [15353037.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):85-93 [1985173.001]
  • [Cites] Prog Clin Biol Res. 1992;377:181-7 [1438414.001]
  • [Cites] Leuk Lymphoma. 1993;11 Suppl 2:141-8 [8124225.001]
  • [Cites] Blood. 1994 Apr 15;83(8):2345-51 [7512845.001]
  • [Cites] Blood. 1994 Jul 15;84(2):380-3 [8025266.001]
  • [Cites] Ann Med. 1996 Apr;28(2):167-73 [8732646.001]
  • [Cites] J Hematother. 1996 Aug;5(4):427-36 [8877718.001]
  • [Cites] Exp Hematol. 1997 Nov;25(12):1261-9 [9357970.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1820-7 [9473251.001]
  • [Cites] Hum Gene Ther. 1998 Oct 10;9(15):2277-84 [9794211.001]
  • [Cites] Bone Marrow Transplant. 1998 Nov;22(10):957-63 [9849692.001]
  • [Cites] Blood. 1999 Mar 1;93(5):1534-9 [10029581.001]
  • [Cites] Blood. 1999 May 1;93(9):3074-80 [10216104.001]
  • [Cites] Cancer Gene Ther. 1999 Sep-Oct;6(5):409-22 [10505851.001]
  • [Cites] Nat Immunol. 2004 Dec;5(12):1266-74 [15502830.001]
  • [Cites] J Biol Chem. 2004 Dec 10;279(50):52210-7 [15471883.001]
  • [Cites] Mol Ther. 2005 Feb;11(2):180-95 [15668130.001]
  • [Cites] J Clin Invest. 2005 Feb;115(2):379-87 [15690085.001]
  • [Cites] Nat Rev Microbiol. 2005 Mar;3(3):201-13 [15738948.001]
  • [Cites] Bone Marrow Transplant. 2005 Jun;35(11):1055-64 [15821774.001]
  • [Cites] Curr Gene Ther. 2005 Aug;5(4):429-43 [16101516.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9982-90 [16267023.001]
  • [Cites] Virology. 2006 Jan 5;344(1):48-54 [16364735.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):298-300 [16507823.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4640-5 [16537421.001]
  • [Cites] Leukemia. 2006 Jun;20(6):911-28 [16642045.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2 Suppl 5):S2-14 [16720198.001]
  • [Cites] Curr Opin Mol Ther. 2006 Aug;8(4):314-21 [16955694.001]
  • [Cites] Nat Med. 2006 Nov;12(11):1310-5 [17086190.001]
  • [Cites] Clin Cancer Res. 2006 Nov 15;12(22):6853-62 [17121907.001]
  • [Cites] J Virol. 2007 Feb;81(3):1251-60 [17108021.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):429-32 [17234747.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Feb;4(2):101-17 [17259931.001]
  • [Cites] Vet Res. 2007 Mar-Apr;38(2):299-318 [17296158.001]
  • [Cites] Bone Marrow Transplant. 2007 Jul;40(1):1-12 [17450184.001]
  • [Cites] Expert Opin Biol Ther. 2007 Sep;7(9):1415-25 [17727330.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8818-27 [17875723.001]
  • [Cites] J Neurovirol. 2007 Dec;13(6):549-60 [18097886.001]
  • [Cites] Mol Ther. 2008 Jan;16(1):52-9 [17998900.001]
  • [Cites] Cell Death Differ. 2008 Feb;15(2):332-43 [18034189.001]
  • [Cites] Mol Ther. 2009 Oct;17(10):1677-82 [19672244.001]
  • [Cites] Leukemia. 2009 Dec;23(12):2313-7 [19865109.001]
  • [Cites] FEMS Microbiol Rev. 2000 Apr;24(2):123-33 [10717311.001]
  • [Cites] Nat Med. 2000 Aug;6(8):879-85 [10932224.001]
  • [Cites] Stem Cells. 2000;18(6):422-7 [11072030.001]
  • [Cites] Clin Cancer Res. 2001 Jan;7(1):51-7 [11205918.001]
  • [Cites] Semin Immunol. 2001 Feb;13(1):73-84 [11289802.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3009-15 [11306480.001]
  • [Cites] J Clin Oncol. 2001 Sep 1;19(17):3771-9 [11533101.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Feb;41(2):241-50 [11856599.001]
  • [Cites] Biochim Biophys Acta. 2008 Jan;1784(1):228-37 [17905673.001]
  • [Cites] Recent Pat Antiinfect Drug Discov. 2006 Nov;1(3):309-21 [18221156.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1218-27 [18281557.001]
  • (PMID = 20211576.001).
  • [ISSN] 1879-0305
  • [Journal-full-title] Cytokine & growth factor reviews
  • [ISO-abbreviation] Cytokine Growth Factor Rev.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI080607-01A1; United States / NIAID NIH HHS / AI / R01 AI080607; United States / NCI NIH HHS / CA / R01 CA138541; United States / NIAID NIH HHS / AI / R01 AI080607-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 76
  • [Other-IDs] NLM/ NIHMS181384; NLM/ PMC2881168
  •  go-up   go-down


63. Parikh SH, Mendizabal A, Martin PL, Prasad VK, Szabolcs P, Driscoll TA, Kurtzberg J: Unrelated donor umbilical cord blood transplantation in pediatric myelodysplastic syndrome: a single-center experience. Biol Blood Marrow Transplant; 2009 Aug;15(8):948-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median age was 11.1 years (range: 1.1-19.7), median weight was 38.6 kg (range: 9.6-62.6), 61% of patients were male, and median time from diagnosis to transplant was 6.6 months (range: 2.0-61.4).
  • Patients with acute myelogenous leukemia (AML) were excluded.
  • Three patients developed acute GVHD (aGVHD) grades II-IV with a cumulative incidence at 100 days of 13% (95% CI 0.0%-27.1.0%).
  • Four patients relapsed with a cumulative incidence of relapse at 3 years of 13.0% (95% CI 0.0%-27.1%).
  • Ten patients died: 3 graft failure, 4 relapse, 2 infections (1 adenovirus, 1 toxoplasmosis), and 1 Epstein-Barr virus (EBV) lymphoproliferative disorder.


64. Usuki K, Nakasone H, Taoka K, Kida M, Iki S, Urabe A: [Transient chromosomal abnormalities following autologous peripheral blood stem cell transplantation for acute myelogenous leukemia]. Rinsho Ketsueki; 2007 Aug;48(8):618-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transient chromosomal abnormalities following autologous peripheral blood stem cell transplantation for acute myelogenous leukemia].
  • Twenty-three patients with acute myelogenous leukemia (AML) have received autologous hematopoietic stem cell transplantation (autoHSCT) in our institute from 1997 to 2005.
  • In these 4 patients with AML1/MTG8 or CBFbeta/MYH11 AML, RT-PCR findings using bone marrow cells were all negative when a cytogenetic abnormality was detected.
  • We present our finding together with a review of the literature on post-autoHSCT cytogenetic abnormalities not related to relapse or secondary leukemia/myelodysplastic syndrome.
  • [MeSH-major] Chromosome Aberrations. Leukemia, Myeloid, Acute / therapy. Peripheral Blood Stem Cell Transplantation / adverse effects


65. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, Chen YH, Zhang XH, Lu DP: Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant; 2009 Feb;15(2):257-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains one of the best therapeutic options to cure acute leukemia (AL).
  • The incidence of grade 2-4 acute graft-versus-host disease (aGVHD) was 45.8%, and that of grades 3 and 4 was 13.4%, which was not associated with the extent of HLA disparity.
  • Seventeen patients received DLI as a treatment for relapse after transplantation and 7 patients achieved leukemia-free survival (LFS).
  • The 3-year probability of LFS for acute myelogenous leukemia (AML) was 70.7% and 55.9%, and for acute lymphoblastic leukemia (ALL) it was 59.7% and 24.8% in standard-risk and high-risk groups, respectively.
  • Lower LFS were associated with diagnosis of acute leukemia in the high-risk group (P= .001, relative risk [RR], 95% confidence interval [CI]: 2.94[1.535-5.631]) and the occurrence of aGVHD of grades 3 and 4 (P= .004).
  • [MeSH-major] Bone Marrow Transplantation / methods. HLA Antigens / immunology. Haplotypes / immunology. Histocompatibility / immunology. Leukemia / therapy. Peripheral Blood Stem Cell Transplantation / methods
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Graft vs Host Disease / immunology. HLA-A Antigens. HLA-B Antigens. HLA-DR Antigens. Humans. Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation, Homologous / immunology. Treatment Outcome. Young Adult


66. Medeiros BC, Minden MD, Schuh AC, Schimmer AD, Yee K, Lipton JH, Messner HA, Gupta V, Chun K, Xu W, Das P, Kamel-Reid S, Brandwein JM: Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (&gt;5 years). Leuk Lymphoma; 2007 Jan;48(1):65-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years).
  • The clinical characteristics and outcome of 15 patients with acute myelogenous leukemia (AML) who experienced relapse at least 5 years after induction of complete remission (very late-relapse AML) are described.
  • There were eight males in this cohort and the median age at diagnosis was 48 years (range 13 - 77 years).
  • The 5-year relapse-free survival and overall survival rates of this cohort were 59% and 51%, respectively.
  • We conclude that very late-relapse AML is a rare event, and that reinduction in these patients is associated with very high CR rates and a potential cure fraction.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis


67. Buccisano F, Maurillo L, Gattei V, Del Poeta G, Del Principe MI, Cox MC, Panetta P, Consalvo MI, Mazzone C, Neri B, Ottaviani L, Fraboni D, Tamburini A, Lo-Coco F, Amadori S, Venditti A: The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia; 2006 Oct;20(10):1783-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia.
  • We assessed by multiparametric flow cytometry the levels of minimal residual disease (MRD) in 100 adult patients with acute myelogenous leukemia (AML) achieving complete remission after intensive chemotherapy.
  • Post-Cons MRD- patients had a superior outcome in terms of relapse rate, overall survival (OS) and relapse-free survival (RFS) (P<0.001, for all comparisons), regardless of the MRD status after induction.
  • Multivariate analysis, including karyotype, age, MDR1 phenotype, post-Ind and post-Cons MRD levels, indicated that the post-Cons MRD status independently affected relapse rate, OS and RFS (P<0.001, for all comparisons).
  • (1) the threshold of 3.5 x 10(-4) is valid in discriminating risk categories in adult AML and (2) post-Cons MRD assessment is critical to predict disease outcome.
  • [MeSH-major] Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / pathology. Neoplasm, Residual / mortality. Neoplasm, Residual / pathology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16838027.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


68. van Besien K, Kunavakkam R, Rondon G, De Lima M, Artz A, Oran B, Giralt S: Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant; 2009 May;15(5):610-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.
  • The purpose of this study was to determine the effect of alemtuzumab on treatment-related mortality (TRM), relapse, overall survival (OS), and disease-free survival (DSF) in patients with acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS) undergoing reduced intensity conditioning (RIC).
  • There were no significant differences in TRM, relapse, survival, and DFS between the 2 groups.
  • The incidence of acute graft-versus-host disease (aGVHD) grade II-IV (relative risk [RR] 5.5, P < .01) and chronic GVHD (cGVHD) (RR 6.6, P < .01) were significantly lower in patients receiving alemtuzumab.
  • The addition of alemtuzumab to an RIC regimen dramatically reduces the incidence of aGVHD and cGVHD in patients with AML and MDS undergoing allogeneic transplantation.
  • TRM, relapse risk, OS and DFS are not affected.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19361753.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K24 CA116471; United States / NCI NIH HHS / CA / P01 CA055164; United States / NCI NIH HHS / CA / R21 CA101337; United States / NCI NIH HHS / CA / 1-R21 CA 101337-01
  • [Publication-type] Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 106XV160TZ / Vidarabine Phosphate; 1X9VK9O1SC / fludarabine phosphate; 3A189DH42V / alemtuzumab; Q41OR9510P / Melphalan
  • [Other-IDs] NLM/ NIHMS589065; NLM/ PMC4348112
  •  go-up   go-down


69. Liu H, Qian WB, Mai WY, Meng HT, Tong HY, Tong Y, Mao LP, Huang J, Wang L, Jiang DZ, Jin J: [HAA regimen as induction chemotherapy for newly diagnosed acute myelogenous leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2008 Jan;29(1):9-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [HAA regimen as induction chemotherapy for newly diagnosed acute myelogenous leukemia].
  • OBJECTIVE: To analyse the outcome of newly diagnosed adult acute myeloid leukemia (AML) patients treated with HAA (homoharringtonine, cytarabine and aclarubicin) regimen and explore the efficacy and safety of this regimen.
  • Kaplan-Meier method was used to estimate relapse free survival (RFS) rate and the differences were compared with 2-sided log-rank test.
  • For the AML-M5 and AML-M /M2 patients the CR rate was 74% and 87% and 3 year RFS of CR patients was 75% and 37%, respectively.
  • CONCLUSION: HAA regimen is a safe, efficacious, and well-tolerable induction therapy for newly diagnosed AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18512308.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Harringtonines; 04079A1RDZ / Cytarabine; 6FG8041S5B / homoharringtonine; 74KXF8I502 / Aclarubicin
  •  go-up   go-down


70. Kara IO, Sahin B, Paydas S, Kara B: Granulocytic sarcoma of the heart: extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone. Leuk Lymphoma; 2005 Jul;46(7):1081-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma of the heart: extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone.
  • A 28-year-old man with relapsed acute myelogenous leukemia (AML-M2) had undergone a non-myeloablative allogeneic peripheral stem cell transplantation.
  • Three years following transplantation, masses were evidenced in his heart by echocardiography but had completely disappeared following a common chemotherapy etoposide, mitoxantrone, ara-C (EMA) regimen for relapsed AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / therapy. Peripheral Blood Stem Cell Transplantation / adverse effects. Sarcoma, Myeloid / drug therapy. Sarcoma, Myeloid / etiology
  • [MeSH-minor] Adult. Cytarabine / administration & dosage. Etoposide / administration & dosage. Heart Neoplasms / diagnosis. Heart Neoplasms / drug therapy. Heart Neoplasms / etiology. Humans. Male. Mitoxantrone / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Remission Induction. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019562.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


71. Fujiwara M, Satou N, Izumi N, Shibasaki Y, Higashimura M, Tsukada N, Koike T: [A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute]. Gan To Kagaku Ryoho; 2007 Nov;34(11):1793-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute].
  • Fifty-seven patients with acute myelogenous leukemia (AML) received the following treatment in our hospital between May 1992 and April 2005.
  • Group A: combination of enocitabine, daunorubicin, 6-mercaptopurine riboside and prednisolone (BHAC-DMP) for remission induction, BHAC-DMP or idarubicin (IDR)+cytarabine (Ara-C) for first consolidation, combination of prednisolone, Ara-C, mitoxantrone and etoposide (PAME) for second consolidation, and PAME for late intensification; Group B: IDR+Ara-C for remission induction, PAME for first consolidation, and high-dose Ara-C+mitoxantrone for second consolidation; Group C (acute promyelocytic leukemia, APL) : all-trans retinoic acid (ATRA) for remission induction, BHAC-DMP or IDR+Ara-C for first consolidation, and PAME for second consolidation.
  • Five-year relapse-free survival rate of the CR patients was 35% in Group A, 49% in Group B, and 70% in Group C.
  • A short duration treatment with intensive consolidation therapy was effective for patients with AML and improved their quality of life (QOL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030012.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; ZRP63D75JW / Idarubicin; ZS7284E0ZP / Daunorubicin; BHAC-DMPV protocol; PAME protocol
  •  go-up   go-down


72. Molnár I, Powell BL: What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia? Curr Hematol Malig Rep; 2007 May;2(2):104-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia?
  • Gemtuzumab ozogamicin (GO) is a novel, targeted chemotherapy designed to treat acute myeloid leukemia (AML).
  • It has been approved in the United States since 2000 to treat CD33+ AML in first relapse in older adults who are not candidates for cytotoxic therapy.
  • Single-agent GO has a limited role in de novo AML.
  • Incorporation of GO into standard induction treatment in de novo and relapsed AML is feasible.
  • [MeSH-major] Aminoglycosides / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Antibodies, Monoclonal / therapeutic use. Immunotoxins / therapeutic use. Leukemia, Myeloid, Acute / drug therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacotherapy. 2001 Oct;21(10 ):1175-80 [11601662.001]
  • [Cites] Leuk Res. 2003 Oct;27(10 ):893-7 [12860008.001]
  • [Cites] Br J Haematol. 2001 Oct;115(1):63-5 [11722411.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1490-6 [11410481.001]
  • [Cites] Am J Clin Pathol. 2002 Oct;118(4):560-6 [12375643.001]
  • [Cites] Leuk Res. 2003 Oct;27(10 ):887-91 [12860007.001]
  • [Cites] Hematol J. 2004;5(3):279-80 [15167917.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1183-8 [15886328.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Dec;50(6):497-500 [12451477.001]
  • [Cites] Leukemia. 2005 Oct;19(10 ):1768-73 [16079891.001]
  • [Cites] Am J Hematol. 2005 Nov;80(3):213-5 [16247755.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3678-84 [10339474.001]
  • [Cites] Leukemia. 2004 May;18(5):983-8 [15029214.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7164s-7170s [16203817.001]
  • [Cites] J Clin Pharmacol. 2004 Aug;44(8):873-80 [15286091.001]
  • [Cites] Haematologica. 2004 Aug;89(8):950-6 [15339678.001]
  • [Cites] Int J Hematol. 2005 Dec;82(5):445-8 [16533750.001]
  • [Cites] Leuk Res. 2005 Sep;29(9):1003-7 [16038726.001]
  • [Cites] Blood. 2002 Jun 15;99(12 ):4343-9 [12036860.001]
  • [Cites] Science. 1988 May 27;240(4856):1198-201 [3240341.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1578-82 [12738663.001]
  • [Cites] Leuk Res. 2005 Jan;29(1):53-7 [15541475.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1995-9 [15187030.001]
  • [Cites] Ann Pharmacother. 2003 Sep;37(9):1182-5 [12921496.001]
  • [Cites] Bone Marrow Transplant. 2005 Apr;35(8):823-4 [15735659.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4277-83 [12933575.001]
  • [Cites] Leuk Lymphoma. 2002 Oct;43(10 ):1951-5 [12481890.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1442-52 [16116598.001]
  • [Cites] Br J Haematol. 2003 Nov;123(4):752-3 [14616990.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1968 [14976063.001]
  • [Cites] Leukemia. 2004 Feb;18(2):316-25 [14614514.001]
  • [Cites] J Clin Pharm Ther. 2006 Aug;31(4):389-92 [16882110.001]
  • [Cites] Ann Hematol. 2006 Jun;85(6):411-2 [16538500.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Jan;51(1):87-90 [12497211.001]
  • [Cites] Eur J Haematol. 2004 Dec;73(6):450-1 [15522070.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1791-5 [15223637.001]
  • [Cites] Ann Oncol. 2004 Aug;15(8):1231-6 [15277263.001]
  • (PMID = 20425358.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibiotics, Antineoplastic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Immunotoxins; 0 / Sialic Acid Binding Ig-like Lectin 3; 93NS566KF7 / gemtuzumab
  • [Number-of-references] 50
  •  go-up   go-down


73. Porter DL, Antin JH: Donor leukocyte infusions in myeloid malignancies: new strategies. Best Pract Res Clin Haematol; 2006;19(4):737-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Donor leukocyte infusion (DLI) provides direct and potent graft-versus-leukemia (GVL) activity to treat relapse after allogeneic stem-cell transplantation.
  • DLI is dramatically effective for relapsed chronic myelogenous leukemia (CML), but has been less effective for relapse of other myeloid malignancies.
  • Nevertheless, most recipients of DLI for relapsed CML, and many patients with relapsed acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS), will experience prolonged remissions and probable cure.
  • Ultimately, the identification of the effector cells and target antigens for GVL induction will lead to the use of tumor-specific adoptive immunotherapy to both prevent and treat relapse with minimal toxicity.
  • Although many issues remain unsettled, the potential to harness the graft-versus-leukemia activity of allogeneic donor cells provides a powerful new paradigm for the immunotherapy of cancer.
  • [MeSH-major] Graft vs Leukemia Effect / immunology. Leukemia, Myeloid / immunology. Leukemia, Myeloid / therapy. Leukocyte Transfusion

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997180.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 99
  •  go-up   go-down


74. Kalaycio M, Advani A, Pohlman B, Sekeres M, Tripp B, Rybicki L, Sobecks R: Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia. Am J Hematol; 2008 Nov;83(11):831-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia.
  • Cytogenetic analysis at the time of diagnosis predicts outcome in patients with acute myelogenous leukemia (AML).
  • For those patients with favorable risk cytogenetics, stem cell transplant can be delayed until the time of relapse.
  • We treated patients with de novo AML and age less than 60 years first with etoposide, mitoxantrone, cytarabine, and G-CSF (EMA-G) to induce remission.
  • Of the 33 patients in remission, 5 year relapse-free survival (RFS) and overall survival (OS) was 46 and 38%, respectively.
  • Our intensive and risk-adapted, stem cell transplant approach to the treatment of patients with AML requires a better definition of risk and does not appear to substantially improve results compared with more standard approaches.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / drug therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • [CommentIn] Am J Hematol. 2008 Nov;83(11):829-30 [18828158.001]
  • (PMID = 18756545.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


75. King ME, Rowe JM: Recent developments in acute myelogenous leukemia therapy. Oncologist; 2007;12 Suppl 2:14-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent developments in acute myelogenous leukemia therapy.
  • Recent progress has been made in several areas in the treatment of acute myelogenous leukemia (AML): prognostic factors, allogeneic bone marrow transplantation, and new and targeted therapies.
  • The use of alternative donors is another advance, and recent data are promising, but survival is poor if transplantation is performed when disease is active, especially during refractory relapse or refractory disease.
  • Cord blood has also been established as a suitable source for hematopoietic transplantation in AML.
  • Therapy can even be tailored to several specific genetic subtypes of AML.
  • [MeSH-major] Leukemia, Myeloid / therapy
  • [MeSH-minor] Acute Disease. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Humans

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18039635.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 41
  •  go-up   go-down


76. Hassane DC, Guzman ML, Corbett C, Li X, Abboud R, Young F, Liesveld JL, Carroll M, Jordan CT: Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood; 2008 Jun 15;111(12):5654-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data.
  • Increasing evidence indicates that malignant stem cells are important for the pathogenesis of acute myelogenous leukemia (AML) and represent a reservoir of cells that drive the development of AML and relapse.
  • Therefore, new treatment regimens are necessary to prevent relapse and improve therapeutic outcomes.
  • Previous studies have shown that the sesquiterpene lactone, parthenolide (PTL), ablates bulk, progenitor, and stem AML cells while causing no appreciable toxicity to normal hematopoietic cells.
  • Thus, PTL must evoke cellular responses capable of mediating AML selective cell death.
  • Given recent advances in chemical genomics such as gene expression-based high-throughput screening (GE-HTS) and the Connectivity Map, we hypothesized that the gene expression signature resulting from treatment of primary AML with PTL could be used to search for similar signatures in publicly available gene expression profiles deposited into the Gene Expression Omnibus (GEO).
  • We therefore devised a broad in silico screen of the GEO database using the PTL gene expression signature as a template and discovered 2 new agents, celastrol and 4-hydroxy-2-nonenal, that effectively eradicate AML at the bulk, progenitor, and stem cell level.
  • These findings suggest the use of multicenter collections of high-throughput data to facilitate discovery of leukemia drugs and drug targets.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Res. 2004 May 1;118(1):53-7 [15093717.001]
  • [Cites] Cancer Control. 2004 Mar-Apr;11(2):97-104 [15024346.001]
  • [Cites] Oncogene. 2004 Sep 20;23(43):7178-87 [15378078.001]
  • [Cites] Bull Narc. 1980;32(3):37-50 [6911030.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Mol Biol Rep. 1997 Mar;24(1-2):45-50 [9228280.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4403-11 [10969785.001]
  • [Cites] Leukemia. 2000 Oct;14(10):1777-84 [11021753.001]
  • [Cites] Brain Res Mol Brain Res. 2000 Dec 28;85(1-2):53-60 [11146106.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2001 Oct;25(7):1341-57 [11513350.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2301-7 [11588023.001]
  • [Cites] Nucleic Acids Res. 2002 Jan 1;30(1):207-10 [11752295.001]
  • [Cites] Bioinformatics. 2002 Feb;18(2):287-97 [11847076.001]
  • [Cites] Bioinformatics. 2002 Mar;18(3):423-33 [11934741.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Dev Neurosci. 2002;24(2-3):161-8 [12401954.001]
  • [Cites] Nat Genet. 2002 Dec;32 Suppl:469-73 [12454640.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16220-5 [12451177.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] J Neurosci Res. 2003 Jul 1;73(1):113-21 [12815715.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Biosci Biotechnol Biochem. 2003 Sep;67(9):1883-7 [14519971.001]
  • [Cites] Genome Biol. 2003;4(10):R70 [14519205.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] J Biol Chem. 1999 Apr 23;274(17):11611-8 [10206970.001]
  • [Cites] J Biol Chem. 1999 Sep 10;274(37):26071-8 [10473555.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4163-9 [15687234.001]
  • [Cites] BMC Bioinformatics. 2005;6:120 [15904488.001]
  • [Cites] BMC Bioinformatics. 2005;6:144 [15941488.001]
  • [Cites] Expert Opin Biol Ther. 2005 Sep;5(9):1147-52 [16120045.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e175 [16284200.001]
  • [Cites] Int Immunopharmacol. 2006 Feb;6(2):109-21 [16399616.001]
  • [Cites] Biofactors. 2005;24(1-4):237-46 [16403984.001]
  • [Cites] BMC Bioinformatics. 2006;7:3 [16398926.001]
  • [Cites] J Clin Invest. 2006 Mar;116(3):808-16 [16485041.001]
  • [Cites] Med Chem. 2006 May;2(3):271-4 [16948473.001]
  • [Cites] N Engl J Med. 2006 Sep 21;355(12):1253-61 [16990388.001]
  • [Cites] Science. 2006 Sep 29;313(5795):1929-35 [17008526.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):321-30 [17010675.001]
  • [Cites] Biochem Pharmacol. 2006 Nov 15;72(10):1311-21 [16984800.001]
  • [Cites] Redox Rep. 2007;12(1):11-5 [17263901.001]
  • [Cites] Redox Rep. 2007;12(1):50-4 [17263909.001]
  • [Cites] Free Radic Biol Med. 2007 Jun 1;42(11):1661-70 [17462534.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2727-35 [17110449.001]
  • [Cites] Nat Biotechnol. 2007 Nov;25(11):1315-21 [17952057.001]
  • [Cites] Trends Mol Med. 2007 Nov;13(11):470-81 [17981087.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4436-44 [17785584.001]
  • [Cites] PLoS Biol. 2004 Sep;2(9):E317 [15340489.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):8992-9002 [14645512.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):257-63 [14770183.001]
  • [CommentIn] Blood. 2008 Jun 15;111(12):5423-4 [18544693.001]
  • (PMID = 18305216.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA090446; United States / NCI NIH HHS / CA / T32 CA009363; United States / NCI NIH HHS / CA / 5T32-CA09363; United States / NCI NIH HHS / CA / R01CA90446
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aldehydes; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents; 0 / Cysteine Proteinase Inhibitors; 0 / Sesquiterpenes; 0 / Terpenes; 0 / Triterpenes; 29343-52-0 / 4-hydroxy-2-nonenal; 2RDB26I5ZB / parthenolide; 34157-83-0 / tripterine
  • [Other-IDs] NLM/ PMC2424160
  •  go-up   go-down


77. Hosing C, Saliba RM, Shahjahan M, Estey EH, Couriel D, Giralt S, Andersson B, Champlin RE, De Lima M: Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant; 2005 Jul;36(2):157-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia.
  • The major cause of failure after allogeneic hematopoietic stem cell transplantation (HSCT) for acute myelogenous leukemia (AML) is disease relapse or progression.
  • We analyzed the outcome of second HSCT for treatment of patients with relapsed, refractory AML/myelodysplastic syndrome (MDS) at our institution.
  • A total of 20 patients (28%) had low leukemia burden as measured by the absence of peripheral blood blasts and <or=5% blasts in the bone marrow at the time of the second transplant.
  • Although, the overall median survival after the second transplant was 6 months, a subset of patients who had low leukemia burden at the time of the second transplant had a 5-year survival of 25 vs 12% in those with a high leukemia burden.
  • [MeSH-major] Leukemia, Myeloid, Acute / prevention & control. Salvage Therapy. Stem Cell Transplantation. Tumor Burden


78. Cooley S, Trachtenberg E, Bergemann TL, Saeteurn K, Klein J, Le CT, Marsh SG, Guethlein LA, Parham P, Miller JS, Weisdorf DJ: Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood; 2009 Jan 15;113(3):726-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.
  • Survival for patients with acute myeloid leukemia (AML) is limited by treatment-related mortality (TRM) and relapse after unrelated donor (URD) hematopoietic cell transplantation (HCT).
  • Natural killer (NK)-cell alloreactivity, determined by donor killer-cell immunoglobulin-like receptors (KIRs) and recipient HLA, correlates with successful HCT for AML.
  • Hypothesizing that donor KIR genotype (A/A: 2 A KIR haplotypes; B/x: at least 1 B haplotype) would affect outcomes, we genotyped donors and recipients from 209 HLA-matched and 239 mismatched T-replete URD transplantations for AML.
  • Multivariate analysis demonstrated a 30% improvement in the relative risk of relapse-free survival with B/x donors compared with A/A donors (RR: 0.70 [95% CI: 0.55-0.88]; P = .002).
  • B/x donors were associated with a higher incidence of chronic graft-versus-host disease (GVHD; RR: 1.51 [95% CI: 1.01-2.18]; P = .03), but not of acute GVHD, relapse, or TRM.
  • This analysis demonstrates that unrelated donors with KIR B haplotypes confer significant survival benefit to patients undergoing T-replete HCT for AML.

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2002 Mar 15;295(5562):2097-100 [11896281.001]
  • [Cites] Am J Transplant. 2008 Jun;8(6):1312-7 [18444913.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13483-8 [14597723.001]
  • [Cites] J Immunol. 2004 Jan 1;172(1):644-50 [14688377.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1521-6 [14504099.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1923-30 [15191952.001]
  • [Cites] Immunol Today. 1990 Jul;11(7):237-44 [2201309.001]
  • [Cites] Nature. 1997 Apr 3;386(6624):510-4 [9087412.001]
  • [Cites] Nat Rev Immunol. 2005 Mar;5(3):201-14 [15719024.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2594-600 [15536148.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4878-84 [15731175.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1446-51 [15973456.001]
  • [Cites] Hum Immunol. 2005 Jul;66(7):836-41 [16112031.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;298:259-77 [16323418.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4370-6 [16131567.001]
  • [Cites] J Exp Med. 2006 Mar 20;203(3):633-45 [16533882.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Aug;12(8):828-36 [16864053.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Aug;12(8):876-84 [16864058.001]
  • [Cites] Bone Marrow Transplant. 2006 Sep;38(6):437-44 [16892071.001]
  • [Cites] Transplantation. 2006 Oct 27;82(8):1024-30 [17060849.001]
  • [Cites] Tissue Antigens. 2007 Apr;69 Suppl 1:42-5 [17445161.001]
  • [Cites] Tissue Antigens. 2007 Apr;69 Suppl 1:92-5 [17445176.001]
  • [Cites] Hum Immunol. 2007 May;68(5):309-23 [17462498.001]
  • [Cites] Clin Exp Immunol. 2007 Jun;148(3):520-8 [17493020.001]
  • [Cites] Blood. 2007 Jun 1;109(11):5058-61 [17317850.001]
  • [Cites] Clin Immunol. 2007 Jun;123(3):272-80 [17446137.001]
  • [Cites] Immunogenetics. 2007 Jul;59(7):525-37 [17464504.001]
  • [Cites] Blood. 2007 Jul 1;110(1):433-40 [17371948.001]
  • [Cites] J Exp Med. 2007 Nov 26;204(12):3027-36 [18025129.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4576-83 [17785583.001]
  • [Cites] Int J Immunogenet. 2008 Feb;35(1):1-8 [18093180.001]
  • [Cites] Blood. 2003 Aug 1;102(3):814-9 [12689936.001]
  • (PMID = 18945962.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518; United States / PHS HHS / / P01 111412; United States / NCI NIH HHS / CA / U24-CA76518
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / Receptors, KIR
  • [Other-IDs] NLM/ PMC2628378
  •  go-up   go-down


79. Clausen J, Wolf D, Petzer AL, Gunsilius E, Schumacher P, Kircher B, Gastl G, Nachbaur D: Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clin Exp Immunol; 2007 Jun;148(3):520-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In patients with acute myelogenous leukaemia or myelodysplastic syndrome (AML/MDS; n = 18), no relapse occurred following transplants meeting both a high (above median) natural killer (NK) cell count and missing HLA-ligand(s) to donor's KIR(s), compared to all other AML/MDS patients (0% versus 44%; P = 0.049).
  • Missing HLA-B and/or HLA-C ligand combined with missing HLA-A3/11 (KIR3DL2 unblocked) predicted for reduced relapse incidence regardless of diagnosis or conditioning type (P = 0.028).
  • Moreover, in AML/MDS patients, this constellation predicted superior overall survival (OS) (P = 0.046).
  • Transplants with more than two different activating donor KIRs were associated with an increased risk for non-relapse mortality (NRM), both by univariate and multivariate analysis.
  • Here, a trend towards reduced relapse incidence was found in patients receiving high numbers of NK cells (16% versus 54%; P = 0.09).
  • By multivariate analysis, relapse risk was decreased significantly in patients receiving high NK cell numbers (P = 0.039).
  • [MeSH-minor] Acute Disease. Chronic Disease. Cytomegalovirus Infections / immunology. Female. Genotype. Graft vs Host Disease / immunology. Graft vs Host Disease / therapy. Graft vs Tumor Effect / genetics. Histocompatibility Testing. Humans. Ligands. Lymphocyte Count. Male. Opportunistic Infections / immunology. Receptors, KIR. Receptors, KIR3DL2. Recurrence. Retrospective Studies. Survival Analysis. Transplantation Conditioning / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Blood Marrow Transplant. 2005 Feb;11(2):122-8 [15682073.001]
  • [Cites] Leuk Lymphoma. 2005 Feb;46(2):177-83 [15621799.001]
  • [Cites] Exp Hematol. 2005 Mar;33(3):279-85 [15730851.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2594-600 [15536148.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2300-6 [15572597.001]
  • [Cites] Bone Marrow Transplant. 2005 Apr;35(7):637-43 [15654351.001]
  • [Cites] Leukemia. 2005 May;19(5):822-8 [15772701.001]
  • [Cites] Blood. 2005 May 15;105(10):4135-42 [15687235.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4878-84 [15731175.001]
  • [Cites] Eur J Haematol. 2006 May;76(5):414-9 [16480430.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Aug;12(8):828-36 [16864053.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Aug;12(8):876-84 [16864058.001]
  • [Cites] Transplantation. 2006 Oct 27;82(8):1024-30 [17060849.001]
  • [Cites] Exp Hematol. 2000 Feb;28(2):119-27 [10706067.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3323-7 [10828011.001]
  • [Cites] Bone Marrow Transplant. 2000 Sep;26(5):489-96 [11019837.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3390-400 [11369628.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3221-7 [11719357.001]
  • [Cites] Biol Blood Marrow Transplant. 2001;7(11):589-95 [11760146.001]
  • [Cites] Science. 2002 Mar 15;295(5562):2097-100 [11896281.001]
  • [Cites] Blood. 2002 Aug 1;100(3):761-7 [12130483.001]
  • [Cites] Bone Marrow Transplant. 2002 Sep;30(5):267-71 [12209347.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4324-30 [12409331.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3825-7 [12393440.001]
  • [Cites] Bone Marrow Transplant. 2003 May;31(10):839-45 [12748658.001]
  • [Cites] Leukemia. 2003 May;17(5):869-75 [12750699.001]
  • [Cites] Bone Marrow Transplant. 2003 Jun;31(11):967-72 [12774046.001]
  • [Cites] Br J Haematol. 2003 Jun;121(6):874-85 [12786798.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1108-13 [12649159.001]
  • [Cites] Blood. 2003 Aug 1;102(3):814-9 [12689936.001]
  • [Cites] Bone Marrow Transplant. 2003 Sep;32(5):505-10 [12942097.001]
  • [Cites] Blood. 2003 Oct 15;102(8):3043-51 [12829583.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1521-6 [14504099.001]
  • [Cites] Tissue Antigens. 2004 Mar;63(3):204-11 [14989709.001]
  • [Cites] Leuk Lymphoma. 2004 Jan;45(1):27-34 [15061194.001]
  • [Cites] Curr Opin Immunol. 2004 Oct;16(5):634-43 [15342011.001]
  • [Cites] N Engl J Med. 1986 Mar 20;314(12):729-35 [3513012.001]
  • [Cites] Nature. 1986 Feb 20-26;319(6055):675-8 [3951539.001]
  • [Cites] J Exp Med. 1996 Apr 1;183(4):1817-27 [8666938.001]
  • [Cites] Immunology. 1997 Dec;92(4):567-70 [9497500.001]
  • [Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]
  • [Cites] Blood. 1999 Jul 1;94(1):333-9 [10381530.001]
  • [Cites] Bone Marrow Transplant. 2004 Dec;34(11):949-54 [15489870.001]
  • [Cites] Br J Haematol. 2005 Mar;128(5):659-67 [15725088.001]
  • (PMID = 17493020.001).
  • [ISSN] 0009-9104
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / KIR3DL2 protein, human; 0 / Ligands; 0 / Receptors, Immunologic; 0 / Receptors, KIR; 0 / Receptors, KIR3DL2
  • [Other-IDs] NLM/ PMC1941931
  •  go-up   go-down


80. Kobayashi R, Kaneda M, Sato T, Ichikawa M, Suzuki D, Ariga T: The clinical feature of invasive fungal infection in pediatric patients with hematologic and malignant diseases: a 10-year analysis at a single institution at Japan. J Pediatr Hematol Oncol; 2008 Dec;30(12):886-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mortality of IFI was 48.2%, excluding patients who died due to relapse and interstitial pneumonitis; in particular, 71.4% patients with a lung lesion (10/14) died due to IFI.
  • Univariate analysis showed that age at diagnosis older than 10 years, relapse of original disease, long-term administration of broad-spectrum antibiotics, and acute myelogenous leukemia (AML) were the risk factors for IFI.
  • AML was most strongly associated using a multivariate analysis.
  • The prognosis of IFI has been expected poor; therefore, prevention of this condition, especially for older patients with AML, would be important.
  • [MeSH-major] Fungemia / diagnosis. Hematologic Neoplasms / diagnosis. Mycoses / diagnosis

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131772.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down


81. Kotzerke J, Bunjes D, Scheinberg DA: Radioimmunoconjugates in acute leukemia treatment: the future is radiant. Bone Marrow Transplant; 2005 Dec;36(12):1021-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioimmunoconjugates in acute leukemia treatment: the future is radiant.
  • Targeted radiotherapy of the bone marrow using radiolabeled monoclonal antibodies is a therapeutic approach of considerable potential for the treatment of acute leukemia in addition to or as a substitute for total body irradiation.
  • The data currently available, of about 300 patients, suggest that radioimmunotherapy (RIT) with beta-emitters in acute leukemia is feasible and safe using a variety of antibodies (anti-CD33, anti-CD45, anti-CD66) and radionuclides (131I, 90Y, 188Re).
  • It appears to reduce the risk of relapse in high-risk acute myelogenous leukemia (AML) patients transplanted early in the course of their disease (<15% blasts) to 20-30%.
  • Furthermore, it has shown the potential to safely intensify reduced-intensity conditioning regimens (nonrelapse mortality of 25% compared to relapse rate of 55% within 2 years).
  • Significant improvements in the results of refractory patients will probably depend on the successful further development of RIT with alpha-emitters or the use of a cocktail of antibodies labeled with alpha- and beta-emitters, in a first dose escalation study of 213Bi-labeled anti-CD33 in refractory AML (partial) remission could be achieved in 5/18 patients.
  • [MeSH-major] Immunoconjugates / therapeutic use. Leukemia / radiotherapy

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247432.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / CD66 antigens; 0 / Cell Adhesion Molecules; 0 / Immunoconjugates; 0 / Radioisotopes; 0 / Sialic Acid Binding Ig-like Lectin 3; 0 / Yttrium Radioisotopes; 7440-15-5 / Rhenium; EC 3.1.3.48 / Antigens, CD45
  • [Number-of-references] 38
  •  go-up   go-down


82. Al-Tonbary Y, Mansour AK, Ghazy H, Elghannam DM, Abd-Elghaffar HA: Prognostic significance of foetal-like tyrosine kinase 3 mutation in Egyptian children with acute leukaemia. Int J Lab Hematol; 2009 Jun;31(3):320-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of foetal-like tyrosine kinase 3 mutation in Egyptian children with acute leukaemia.
  • In children with acute myelogenous leukaemia (AML), internal tandem duplication of the Flt3 gene (Flt3/ITD) was previously reported and correlated to poor prognosis.
  • Limited data are available about childhood acute lymphoblastic leukaemia (ALL).
  • We analysed bone marrow specimens from 55 newly diagnosed acute leukaemia cases including 30 AML and 25 ALL by genomic PCR for the presence of Flt3/ITD and correlated its presence with clinical outcome.
  • Tandem duplication was found in 6/30(20%) AML cases: 2/8 M1, 1/8 M2, 2/6 M3, 1/6 M4 with loss of heterozygosity (LOH) in two cases.
  • Patients with Flt3/ITD appear to be refractory to primary induction therapy, and for those who achieve remission, there is a high rate of relapse and death so there may be an association between this type of mutation and patient outcome.
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. fms-Like Tyrosine Kinase 3 / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18336585.001).
  • [ISSN] 1751-553X
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


83. Kröger N, Brand R, van Biezen A, Cahn JY, Slavin S, Blaise D, Sierra J, Zander A, Niederwieser D, de Witte T, Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT): Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant; 2006 Jan;37(2):183-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
  • We report the results of 65 patients with treatment-related myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) who were transplanted from an autograft and reported to the EBMT.
  • The primary disease was solid tumors (n = 37), Hodgkin's disease (n = 13), non-Hodgkin's lymphoma (n = 10), acute lymphoblastic leukemia (n = 2) or myeloproliferative syndromes (n = 3).
  • The types of MDS were as follows: RAEB (n = 1; 2%), RAEB-t (n = 3; 5%), or AML (n = 56; 87%).
  • The median time between diagnosis and transplantation was 5 months (range, 3-86).
  • The cumulative incidence of relapse was 58% (95% CI: 44-72%) and of treatment-related mortality 12% (95% CI: 6-38%).
  • Lower relapse rate was seen in patients transplanted in first complete remission (CR1 vs non-CR1: 3 years: 48 vs 89%; P = 0.05).
  • Autologous transplantation may cure a substantial number of patients with treatment-related MDS/AML, especially if they are in CR1 and of younger age.
  • [MeSH-major] Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy. Myelodysplastic Syndromes / mortality. Myelodysplastic Syndromes / therapy. Neoplasms, Second Primary / mortality. Neoplasms, Second Primary / therapy. Stem Cell Transplantation

  • Genetic Allia